Details of the Drug

General Information of Drug (ID: DMVP5YE)

• Drug Name: Doxorubicin
• Synonyms: doxorubicin; 23214-92-8; Doxil; Doxorubicine; Adriablastin; Doxorubicinum; 14-Hydroxydaunomycin; 14-Hydroxydaunorubicine; Doxorubicina; Adriamycin semiquinone; Doxorubicinum [INN-Latin]; Doxorubicine [INN-French]; Doxorubicina [INN-Spanish]; Myocet; FI 106; Doxorubicin [USAN:INN:BAN]; CCRIS 739; NDC 38242-874; HSDB 3070; UNII-80168379AG; NCI-C01514; EINECS 245-495-6; CHEMBL53463; CHEBI:28748; 5,12-Naphthacenedione,; ADM; ADR; ThermoDox; Aerosolized Doxorubicin; Doxorubicin citrate; RDF Rubex; Conjugate of doxorubicin with humanized monoclonal antibody LL1 against CD74; DM2; JT9100000; Adiblastine (hydrochloride salt); Adr iablatina (hydrochloride salt); Adriablastine (hydrochloride salt); Adriablatina (hydrochloride salt); Adriacin (hydrochloride salt); Adriamycin PFS (TN); Adriamycin PFS (hydrochloride salt); Adriamycin RDF (TN); Adriamycin RDF (hydrochloride salt); Adriblastina (TN); Adriblastina (hydrochloride salt); Adriblatina (hydrochloride salt); Caelyx (TN); Conjugate of doxorubicin with monoclonal antibody P4/D10 against GP120; DOX-SL; Doxorubicin hydrochloride (hydrochloride salt); Doxorubicin-hLL1; Doxorubicin-hLL1 conjugate; Farmablastina (hydrochloride salt); Hydroxydaunomycin hydrochlor ide (hydrochloride salt); Hydroxydaunomycin hydrochloride (hydrochloride salt); Hydroxydaunorubicin hydrochloride (hydrochloride salt); Myocet (TN); Rubex (TN); Rubex (hydrochloride salt); TLC D-99; Doxorubicin (USAN/INN); Doxorubicin-P4/D10; Doxorubicin-P4/D10 conjugate; Cantide + adriamycin

Indication

Disease Entry	ICD 11	Status	REF
Acute myelogenous leukaemia	2A41	Approved	[1]
Adult kidney Wilms tumor	N.A.	Approved	[1]
Anterior urethra cancer	N.A.	Approved	[1]
Beckwith-Wiedemann syndrome	N.A.	Approved	[1]
Breast carcinoma	N.A.	Approved	[1]
Burkitt lymphoma	N.A.	Approved	[1]
Carcinoma	2A00-2F9Z	Approved	[1]
Childhood kidney Wilms tumor	N.A.	Approved	[1]
Epithelial ovarian cancer	2B5D	Approved	[1]
Fallopian tube neoplasm	N.A.	Approved	[1]
Hamartoma	N.A.	Approved	[1]
Hormone-resistant prostate carcinoma	N.A.	Approved	[1]
Inflammatory breast cancer	2C62	Approved	[1]
Kaposi sarcoma	2B57	Approved	[1]
Kidney neoplasm	N.A.	Approved	[1]
Leukemia	N.A.	Approved	[1]
Lung cancer	2C25.0	Approved	[1]
MALT lymphoma	N.A.	Approved	[1]
Nodal marginal zone lymphoma	2A85.0	Approved	[1]
Ovarian disorder	N.A.	Approved	[1]
Ovarian neoplasm	N.A.	Approved	[1]
Plasma cell myeloma	2A83.1	Approved	[1]
Posterior urethra cancer	N.A.	Approved	[1]
Primary systemic amyloidosis	N.A.	Approved	[1]
Small-cell lung cancer	2C25.Y	Approved	[1]
Solid tumour/cancer	2A00-2F9Z	Approved	[2]
Splenic marginal zone lymphoma	N.A.	Approved	[1]
Testicular lymphoma	N.A.	Approved	[1]
Thyroid cancer	2D10	Approved	[1]
Wilms tumor	N.A.	Approved	[1]
Hepatocellular carcinoma	2C12.02	Phase 3	[3]
Breast cancer	2C60-2C65	Phase 2	[4]
Classic Hodgkin lymphoma	N.A.	Investigative	[1]
Follicular lymphoma	2A80	Investigative	[1]
Neuroblastoma	2D11.2	Investigative	[1]
Tumour	2A00-2F9Z	Investigative	[5]

• Therapeutic Class: Anticancer Agents
• Affected Organisms: Humans and other mammals
• ATC Code:
  L01DB01: Doxorubicin
  L01DB: Anthracyclines and related substances
  L01D: CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES
  L01: ANTINEOPLASTIC AGENTS
  L: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 3:
  Molecular Weight (mw); 543.5
  Logarithm of the Partition Coefficient (xlogp); 1.3
  Rotatable Bond Count (rotbonds); 5
  Hydrogen Bond Donor Count (hbonddonor); 6
  Hydrogen Bond Acceptor Count (hbondacc); 12
• ADMET Property:
  BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [6]
  Clearance: The drug present in the plasma can be removed from the body at the rate of 15 mL/min/kg [7]
  Elimination: 3.5% of drug is excreted from urine in the unchanged form [6]
  Half-life: The concentration or amount of drug in body reduced by one-half in 20 - 48 hours [7]
  Metabolism: The drug is metabolized via several oxidoreductases to form a doxirubicin-semiquinone radical []
  MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 4.47076 micromolar/kg/day [8]
  Unbound Fraction: The unbound fraction of drug in plasma is 0.28% [7]
  Vd: Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 22 L/kg [7]
  Water Solubility: The ability of drug to dissolve in water is measured as 10 mg/mL [6]

Adverse Drug Reaction (ADR)

ADR Term	Variation	Related DOT	DOT ID	REF
Cardiotoxicity	rs7853758	SLC28A3	OT5TLTYU	[9]
Cardiotoxicity	rs17863783	UGT1A6	OTGTQ2C9	[9]
Cardiotoxicity	Not Available	TNNI2	OTGGZFSC	[10]
Cytogenetic investigations	Not Available	TOP1	OT51O0CF	[10]
Electrolyte imbalance	Not Available	BGLAP	OTK1YLWQ	[10]
Electrolyte imbalance	Not Available	PTH1R	OTQF5ZAK	[10]
Neutropenia	rs2512987	ME3	OT3XMLYG	[11]

• Chemical Identifiers:
  Formula: C27H29NO11
  IUPAC Name: (7S,9S)-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione
  Canonical SMILES: C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O
  InChI: InChI=1S/C27H29NO11/c1-10-22(31)13(28)6-17(38-10)39-15-8-27(36,16(30)9-29)7-12-19(15)26(35)21-20(24(12)33)23(32)11-4-3-5-14(37-2)18(11)25(21)34/h3-5,10,13,15,17,22,29,31,33,35-36H,6-9,28H2,1-2H3/t10-,13-,15-,17-,22+,27-/m0/s1
  InChIKey: AOJJSUZBOXZQNB-TZSSRYMLSA-N
• Cross-matching ID:
  PubChem CID: 31703
  ChEBI ID: CHEBI:28748
  CAS Number: 23214-92-8
  UNII: 80168379AG
  DrugBank ID: DB00997
  TTD ID: D07VLY
  VARIDT ID: DR00301
  INTEDE ID: DR0546
• Repurposed Drugs (RPD): Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
DNA topoisomerase II (TOP2)	TT0IHXV	TOP2A_HUMAN ; TOP2B_HUMAN	Modulator	[12]
TERT messenger RNA (TERT mRNA)	TTQY2EJ	TERT_HUMAN	Not Available	[5]

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
ATP-binding cassette sub-family B member 8 (ABCB8)	DT0KQND	ABCB8_HUMAN	Substrate	[13]
ATP-binding cassette sub-family B member 5 (ABCB5)	DTKVEXO	ABCB5_HUMAN	Substrate	[14]
Fly-like putative transporter 2 (SLC22A16)	DTPATLS	S22AG_HUMAN	Substrate	[15]
Monocarboxylate transporter 1 (SLC16A1)	DT342ZG	MOT1_HUMAN	Substrate	[16]
Multidrug resistance-associated protein 2 (ABCC2)	DTFI42L	MRP2_HUMAN	Substrate	[17]
Multidrug resistance-associated protein 1 (ABCC1)	DTSYQGK	MRP1_HUMAN	Substrate	[18]
Breast cancer resistance protein (ABCG2)	DTI7UX6	ABCG2_HUMAN	Substrate	[19]
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[20]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Substrate	[21]
Cytochrome P450 2D6 (CYP2D6)	DECB0K3	CP2D6_HUMAN	Substrate	[22]
Cytochrome P450 3A5 (CYP3A5)	DEIBDNY	CP3A5_HUMAN	Substrate	[23]
Quinone reductase 1 (NQO1)	DENP5RY	NQO1_HUMAN	Substrate	[24]
Nitric oxide synthase inducible (NOS2)	DE3C1JY	NOS2_HUMAN	Substrate	[25]
Nitric oxide synthase endothelial (NOS3)	DE708H2	NOS3_HUMAN	Substrate	[25]
NADPH-cytochrome P450 reductase (CPR) Main DME	DE3N2FM	NCPR_HUMAN	Substrate	[26]
Aldo-keto reductase 1C3 (AKR1C3)	DEGQTXO	AK1C3_HUMAN	Substrate	[27]
Nitric oxide synthase brain (NOS1)	DEYEK78	NOS1_HUMAN	Substrate	[25]
Aldo-keto reductase 1A1 (AKR1A1)	DED2FW3	AK1A1_HUMAN	Substrate	[28]
Xanthine dehydrogenase/oxidase (XDH) Main DME	DECG04O	XDH_HUMAN	Substrate	[29]
NADH-ubiquinone oxidoreductase 30 kDa (NDUFS3)	DE741FI	NDUS3_HUMAN	Substrate	[24]
NADH-ubiquinone oxidoreductase 49 kDa (NDUFS2)	DEKX5CD	NDUS2_HUMAN	Substrate	[24]
Methionine synthase reductase (MTRR)	DE6NIY9	MTRR_HUMAN	Substrate	[30]
Succinic semialdehyde reductase (AKR7A2)	DE4G629	ARK72_HUMAN	Substrate	[31]
NADH-ubiquinone oxidoreductase 20 kDa (NDUFS7)	DEIW03B	NDUS7_HUMAN	Substrate	[24]
NADH dehydrogenase (nuoE)	DEAMEF2	J9VB37_9ACTN	Substrate	[32]
Molybdopterin-dependent enzyme (molD)	DEME01W	A0A327UAE0_9ACTN	Substrate	[33]
Molybdopterin-dependent enzyme (molD)	DEYSOD0	A0A327SQQ7_9ACTN	Substrate	[33]
Molybdopterin-dependent enzyme (molD)	DE1QMDG	A0A327U7N1_9ACTN	Substrate	[33]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
(E3-independent) E2 ubiquitin-conjugating enzyme	OTHGS2VA	UBE2O_HUMAN	Gene/Protein Processing	[34]
1,4-alpha-glucan-branching enzyme (GBE1)	OTK2N05B	GLGB_HUMAN	Gene/Protein Processing	[34]
1-acyl-sn-glycerol-3-phosphate acyltransferase delta (AGPAT4)	OT5CTQKO	PLCD_HUMAN	Gene/Protein Processing	[34]
1-acyl-sn-glycerol-3-phosphate acyltransferase gamma (AGPAT3)	OTAUR5TG	PLCC_HUMAN	Gene/Protein Processing	[34]
1-acylglycerol-3-phosphate O-acyltransferase ABHD5 (ABHD5)	OTY829Z3	ABHD5_HUMAN	Gene/Protein Processing	[34]
1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase beta-1 (PLCB1)	OT9HYT7A	PLCB1_HUMAN	Gene/Protein Processing	[34]
1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase beta-2 (PLCB2)	OTPAHDGO	PLCB2_HUMAN	Gene/Protein Processing	[34]
1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase beta-3 (PLCB3)	OT0OMDEM	PLCB3_HUMAN	Gene/Protein Processing	[34]
1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase beta-4 (PLCB4)	OTPA0QHW	PLCB4_HUMAN	Gene/Protein Processing	[34]
1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase delta-1 (PLCD1)	OT6WFVXZ	PLCD1_HUMAN	Gene/Protein Processing	[34]

Experimental Cancer Drug Sensitivity Information

Cancer Drug Sensitivity Data Curated from 43 Cell Line(s) in Bone Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
RPMI-3460/CS1	GDSC1	-2.0225	2.7798	-2.5518	43.601
EW-16	GDSC1	-7.6103	-4.0469	-7.6174	87.2855
ES4	GDSC1	-7.2323	-2.109	-7.3085	80.819
EW-13	GDSC1	-6.2757	-2.4236	-6.3016	78.1924
ES1	GDSC1	-6.0754	-3.658	-6.0765	79.8655
ES8	GDSC1	-5.4867	-3.3462	-5.4873	75.1896
ES7	GDSC1	-5.3695	-2.9885	-5.3713	73.8539
EW-7	GDSC1	-5.0171	-0.7083	-5.1079	67.9578
SK-PN-DW	GDSC1	-4.9252	-2.8728	-4.926	70.1046
EW-22	GDSC1	-4.7911	-1.6629	-4.8103	81.3913
SK-ES-1	GDSC1; CTRP2	-4.4545	-1.25	-4.4567	69.5215
MHH-ES-1	GDSC1; CTRP2	-4.438	-2.187	-4.438	69.7536
EW-1	GDSC1	-4.1537	-1.597	-4.1626	62.5692
HOS	GDSC1; CTRP2	-4.0709	-1.346	-4.0716	67.234
A-673	GDSC1; CTRP2	-3.6626	-0.7294	-3.6645	64.5099
TC71	CTRP2	-2.9548	-0.2828	-2.9563	59.9013
U2OS	GDSC1; CTRP2	-2.9497	0.9646	-2.9725	59.5977
NOS-1 [Human HNSCC]	GDSC1	-2.8905	2.358	-3.3765	50.5281
CAL-72	GDSC1	-2.6575	7.0056	-4.8455	49.1591
SaOS-2	GDSC1; CTRP2	-2.6087	3.1512	-2.7952	56.7998
ES5	GDSC1	-2.533	2.0895	-2.9147	47.6407
SK-N-MC	CTRP2	-2.3528	-2.0089	-2.3528	55.9432
H-EMC-SS	GDSC1	-2.3523	1.8869	-2.6673	46.033
EW-3	GDSC1	-1.9579	2.0013	-2.2653	42.5452
SW1353	CTRP2	-1.8869	0.4839	-1.8883	52.8339
CHSA0108	GDSC1	-1.8716	2.2281	-2.2293	41.9051
NY	GDSC1	-1.6197	1.7422	-1.8364	39.1712
ES6	GDSC1	-1.5724	2.7495	-2.0521	39.6007
EW-18	GDSC1	-1.5674	2.0628	-1.8548	38.9326
SJSA-1	GDSC1; CTRP2	-1.5499	4.8562	-1.9519	50.5099
CHSA8926	GDSC1	-1.079	5.7383	-2.667	38.6424
EW-11	GDSC1	-0.8956	5.8434	-2.524	37.3937
CHSA0011	GDSC1	-0.5648	1.7594	-0.6946	28.7009
CAL-78	GDSC1; CTRP2	-0.5405	2.2672	-0.5552	43.9067
TC-71	GDSC1	-0.4334	0.7425	-0.4395	26.8124
HuO-3N1	GDSC1	-0.1923	5.9926	-1.8759	32.1509
EW-24	GDSC1	-0.1922	2.2517	-0.403	25.5011
HuO9	GDSC1	-0.1023	1.1269	-0.1168	23.6355
G-292 clone A141B1	GDSC1; CTRP2	1.2453	7.7823	0.2474	34.9434
CADO-ES1	GDSC1	1.6061	4.695	0.4964	17.1194
Hs 822.T	CTRP2	2.5063	6.9569	1.9004	25.693
Hs 888.T	CTRP2	2.941	8.0179	1.9704	24.1568
MG-63	GDSC1; CTRP2	3.5557	14.7887	-0.5426	30.0763

Cancer Drug Sensitivity Data Curated from 220 Cell Line(s) in Haematopoietic And Lymphoid Tissue Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
JK1	CTRP2	-6.6607	-3.687	-6.661	83.1357
MEC1	CTRP2	-3.1463	0.8856	-3.1707	60.8089
JM1	GDSC1; CTRP2	-4.8228	-1.9958	-4.8233	72.0647
EoL-1	GDSC1; CTRP2	-9.0157	-3.0958	-9.0357	87.7908
MOLT-16	GDSC1; CTRP2	-8.0503	-4.9992	-8.0504	90.0446
SU-DHL-5	GDSC1	-7.6022	-6.5307	-7.6022	94.6252
MHH-CALL-4	CTRP2	-7.4579	-5.081	-7.4579	88.357
SUP-B15	GDSC1; CTRP2	-7.3954	-5.929	-7.3954	89.1342
Reh	GDSC1; CTRP2	-7.2458	-5.939	-7.2458	88.3272
SU-DHL-8	GDSC1; CTRP2	-7.0282	-3.7697	-7.0286	84.7256
RCH-ACV	GDSC1; CTRP2	-6.7282	-4.4611	-6.7282	84.3489
MV4-11	GDSC1; CTRP2	-6.7124	-3.7318	-6.7127	83.4171
MOLT-3	CTRP2	-6.5925	-6.021	-6.5925	84.1884
OCI-Ly19	GDSC1; CTRP2	-6.4363	-3.8355	-6.4364	82.2687
EB1	CTRP2	-6.4146	-1.8708	-6.4245	79.5155
DoHH2	GDSC1; CTRP2	-6.3393	-4.0164	-6.3393	81.938
OCI-Ly3	CTRP2	-6.3376	-4.6417	-6.3376	82.3228
697	GDSC1; CTRP2	-6.3208	-4.9565	-6.3208	82.3206
KE-97	CTRP2	-6.2915	-2.9478	-6.2925	80.5732
HuNS1	CTRP2	-6.0655	-2.5524	-6.0671	79.0746
RS4;11	GDSC1; CTRP2	-6.0436	-4.5295	-6.0436	80.4666
Ri-1	CTRP2	-5.9514	3.9301	-6.5362	69.5506
SEM	CTRP2	-5.9147	-5.0109	-5.9147	79.6715
BV-173	GDSC1; CTRP2	-5.8606	-3.0527	-5.8608	78.595
CTV-1	GDSC1	-5.8279	-3.9788	-5.828	78.5987
MM1.S	CTRP2	-5.7515	-4.2874	-5.7515	78.5507
Daudi	GDSC1; CTRP2	-5.7499	-1.5379	-5.758	76.4148
NU-DUL-1	GDSC1; CTRP2	-5.7145	-3.4309	-5.7145	78.0426
NALM-6	GDSC1; CTRP2	-5.685	-3.551	-5.685	77.9258
KMS-34	CTRP2	-5.6574	-4.9536	-5.6574	77.9589
Kasumi-2	CTRP2	-5.6293	-4.083	-5.6293	77.7309
MOLT-4	GDSC1	-5.625	-4.0659	-5.625	76.9968
KE-37	GDSC1; CTRP2	-5.5925	-3.972	-5.5925	77.4763
WIL2 NS	GDSC1	-5.5505	-2.3201	-5.5643	74.0627
SR	GDSC1; CTRP2	-5.5118	-2.6568	-5.5122	76.404
SUP-T11	CTRP2	-5.501	-2.6289	-5.5014	76.3245
QIMR-WIL	GDSC1	-5.4889	-2.6566	-5.4949	74.2413
Farage	GDSC1	-5.4242	-2.3905	-5.4342	73.367
MOLM-13	GDSC1; CTRP2	-5.406	-2.6647	-5.4063	75.8193
Mono-Mac-1	CTRP2	-5.4036	-2.0848	-5.4051	75.3639
CCRF-CEM	GDSC1	-5.3727	-3.0408	-5.3742	73.9422
Hs 611.T	CTRP2	-5.3261	-1.6828	-5.3296	74.5972
Mino	CTRP2	-5.2145	-2.1396	-5.2154	74.3935
MHH-CALL-3	CTRP2	-5.2039	2.1475	-5.4282	69.4273
SIG-M5	GDSC1; CTRP2	-5.2012	-3.3041	-5.2012	74.8469
EB2	GDSC1	-5.197	-3.3928	-5.1972	72.8182
Loucy	GDSC1	-5.1081	-2.5162	-5.1125	71.2694
Hs 445	GDSC1	-5.0694	-1.3192	-5.1137	69.2715
CRO-AP2	GDSC1	-5.0269	-3.7218	-5.0269	89.72
SKM-1	GDSC1; CTRP2	-5.0145	-3.3526	-5.0145	73.6492
MOLM-6	CTRP2	-4.9738	-0.6397	-4.9886	71.823
NKM-1	GDSC1	-4.9449	-1.4992	-4.9751	68.7101
CML-T1	GDSC1; CTRP2	-4.9272	-3.3755	-4.9272	73.0787
KMS-26	CTRP2	-4.8937	-2.0917	-4.8942	72.5312
KMS-21-BM	CTRP2	-4.889	-2.3355	-4.8891	72.6117
SU-DHL-10	GDSC1; CTRP2	-4.8423	-1.1617	-4.8473	71.632
OCI-AML-2	GDSC1; CTRP2	-4.8368	-2.5232	-4.8369	72.3547
MY-M12	GDSC1	-4.8229	-2.3621	-4.8518	60.0748
U-937	CTRP2	-4.8053	-2.3892	-4.8054	72.1177
SU-DHL-6	GDSC1; CTRP2	-4.8003	-1.4835	-4.8026	71.6389
HC-1	GDSC1	-4.7907	-1.4493	-4.8187	67.5466
P12-Ichikawa	GDSC1; CTRP2	-4.7785	-3.0595	-4.7785	72.0788
KMS-27	CTRP2	-4.7269	-3.1418	-4.7269	71.7463
SUP-M2	GDSC1; CTRP2	-4.6963	-2.6941	-4.6963	71.5004
JVM-3	GDSC1; CTRP2	-4.6848	-1.1889	-4.6885	70.7961
MOLP-2	CTRP2	-4.6592	0.9314	-4.7339	68.696
KOPN-8	GDSC1	-4.6286	-0.272	-4.7442	64.8472
RPMI-8402	GDSC1; CTRP2	-4.6184	-3.3121	-4.6184	71.0342
THP-1	GDSC1; CTRP2	-4.6081	-1.977	-4.6084	70.7624
BE-13	GDSC1	-4.6007	-3.3772	-4.6007	67.2775
CESS	GDSC1	-4.5614	-2.6379	-4.5621	66.7394
NU-DHL-1	CTRP2	-4.5297	-0.7482	-4.5371	69.6314
MOTN-1	CTRP2	-4.5258	-0.2993	-4.5415	69.2578
MOLT-13	GDSC1; CTRP2	-4.5223	-1.857	-4.5227	70.1932
L-540	GDSC1; CTRP2	-4.383	-1.7912	-4.3833	69.31
A3/Kawakami	GDSC1; CTRP2	-4.3544	-1.7545	-4.3548	69.1213
MOLM-16	GDSC1; CTRP2	-4.3313	-0.1206	-4.3483	68.092
P30/OHK	GDSC1	-4.3113	-2.732	-4.3114	64.4345
H9	GDSC1	-4.199	-1.9127	-4.2029	63.1374
ATN-1	GDSC1	-4.1933	-3.3437	-4.1933	63.3296
HPB-ALL	CTRP2	-4.1813	0.1236	-4.2024	67.1068
NB4	GDSC1; CTRP2	-4.164	-2.38	-4.164	67.9951
Karpas-231	GDSC1	-4.1635	-3.1661	-4.1635	63.0395
JSC-1	GDSC1	-4.1141	0.2284	-4.2608	60.7287
GA-10	GDSC1; CTRP2	-4.0712	0.3856	-4.0987	66.3244
MOLP-8	GDSC1; CTRP2	-4.0328	-1.2165	-4.0338	66.9589
NCO2	CTRP2	-4.0264	-1.3347	-4.027	66.9515
PF-382	GDSC1; CTRP2	-3.9733	-2.0776	-3.9733	66.7216
SU-DHL-1	GDSC1; CTRP2	-3.9654	-2.5684	-3.9654	66.685
IM-9	GDSC1	-3.9227	-2.4211	-3.9228	60.6823
Namalwa	GDSC1; CTRP2	-3.9044	-0.8737	-3.9065	66.0559
DND-41	GDSC1; CTRP2	-3.8859	-1.6368	-3.886	66.1098
KYO-1	CTRP2	-3.834	-1.4398	-3.8342	65.7468
TUR	GDSC1	-3.7848	-2.0986	-3.7853	59.3296
ALL-SIL	GDSC1; CTRP2	-3.7845	-2.1765	-3.7845	65.4777
ALL-PO	GDSC1	-3.7704	-1.2259	-3.7823	58.9809
Granta-519	GDSC1; CTRP2	-3.6959	1.2189	-3.7526	63.7317
Ki-JK	CTRP2	-3.6932	-0.458	-3.6971	64.6168
SCC-3	GDSC1	-3.6888	-2.7332	-3.689	46.539
BC-1	GDSC1	-3.6884	-0.719	-3.7197	58.0322
KMS-12-BM	GDSC1; CTRP2	-3.6743	-0.6293	-3.6768	64.5551
MC116	GDSC1; CTRP2	-3.6739	0.6776	-3.7029	63.96
NCI-H929	GDSC1; CTRP2	-3.665	-1.7325	-3.665	64.6711
RPMI-6666	GDSC1; CTRP2	-3.6497	0.2831	-3.6655	64.0398
DEL	GDSC1; CTRP2	-3.5786	-2.0452	-3.5786	64.1077
KMS-28BM	CTRP2	-3.5639	1.8127	-3.6586	62.6295
SUP-T1	GDSC1; CTRP2	-3.5181	-0.5023	-3.5207	63.544
Jurkat	GDSC1; CTRP2	-3.5173	-2.3674	-3.5173	63.7015
L-363	GDSC1; CTRP2	-3.4826	-0.1646	-3.4881	63.2256
AML-193	CTRP2	-3.4407	-1.5644	-3.4407	63.1824
WSU-DLCL2	GDSC1; CTRP2	-3.4342	-1.5927	-3.4342	63.1403
SUP-HD1	GDSC1; CTRP2	-3.4219	0.1242	-3.4311	62.7555
EM-2	GDSC1; CTRP2	-3.4112	-1.2965	-3.4113	62.9749
KHM-1B	CTRP2	-3.4068	-2.4196	-3.4068	62.9654
OCI-AML-5	GDSC1; CTRP2	-3.3834	-0.3691	-3.3862	62.6637
CTB-1	GDSC1	-3.38	0.597	-3.5288	54.8187
Ku812	GDSC1; CTRP2	-3.3669	0.4048	-3.3812	62.3171
VL51	GDSC1	-3.3585	0.8879	-3.5529	54.5278
Karpas-299	GDSC1; CTRP2	-3.3476	-1.7134	-3.3476	62.5681
RPMI-8226	GDSC1; CTRP2	-3.3405	-0.6147	-3.3418	62.4394
AMO1	GDSC1; CTRP2	-3.3103	-0.0602	-3.3155	62.1267
ST486	GDSC1; CTRP2	-3.3054	-2.3148	-3.3054	62.2894
DB	GDSC1; CTRP2	-3.223	0.0896	-3.2294	61.5419
OCI-Ly10	CTRP2	-3.1823	0.0845	-3.1883	61.289
EHEB	GDSC1; CTRP2	-3.1706	-0.1663	-3.1738	61.2719
MLMA	GDSC1	-3.1123	-0.3635	-3.1444	52.7309
KM-H2	GDSC1; CTRP2	-3.1098	-0.5922	-3.1105	60.943
ARH-77	GDSC1	-3.0658	-0.611	-3.0836	52.323
JVM-2	GDSC1; CTRP2	-3.0596	0.983	-3.0855	60.2537
P32/ISH	GDSC1	-3.0514	-1.4321	-3.0524	52.2264
WSU-NHL	GDSC1	-3.0228	0.9647	-3.2043	51.7352
M-07e	CTRP2	-3.0119	0.2591	-3.0187	60.1767
BL-41	GDSC1; CTRP2	-2.9551	0.4937	-2.9652	59.765
RL	GDSC1; CTRP2	-2.8418	1.0488	-2.865	58.9132
HL-60	GDSC1; CTRP2	-2.7348	-1.0723	-2.7349	58.4872
Raji	GDSC1; CTRP2	-2.7324	1.2714	-2.7617	58.1797
ML-2	GDSC1	-2.7183	0.5774	-2.819	49.056
SU-DHL-16	GDSC1	-2.7167	0.2374	-2.7787	49.021
U-698-M	GDSC1	-2.6896	-1.1989	-2.6904	48.7147
Jiyoye	GDSC1	-2.6871	-0.3436	-2.7064	48.7101
OCI-AML-3	GDSC1; CTRP2	-2.6683	-0.1952	-2.6693	58.0205
SUP-B8	GDSC1	-2.6482	-1.5095	-2.6483	62.1087
BALL-1	GDSC1	-2.6369	-1.0864	-2.6382	48.2043
VAL	GDSC1	-2.6093	1.9804	-2.9704	48.258
JURL-MK1	GDSC1; CTRP2	-2.607	-0.6576	-2.6071	57.6327
BC-3	GDSC1	-2.5846	-0.112	-2.7852	33.9272
HEL	GDSC1; CTRP2	-2.5184	-0.8117	-2.5184	57.0454
HEL 92.1.7	CTRP2	-2.5119	-1.99	-2.5119	57.0035
CA46	GDSC1; CTRP2	-2.5035	1.5114	-2.5372	56.7109
MJ	CTRP2	-2.4697	15.6256	-6.8942	52.8643
LC4-1	GDSC1	-2.4634	0.4483	-2.5332	46.6579
Peer	CTRP2	-2.4576	0.4639	-2.462	56.5903
NOMO-1	GDSC1; CTRP2	-2.4476	-1.0865	-2.4476	56.5749
HH [Human lymphoma]	GDSC1; CTRP2	-2.4054	0.032	-2.4065	56.2775
A4/Fukuda	GDSC1; CTRP2	-2.4003	0.0574	-2.4015	56.2429
Kasumi-1	GDSC1; CTRP2	-2.3992	1.0172	-2.4128	56.1472
OCI-M1	GDSC1; CTRP2	-2.3914	-0.8262	-2.3914	56.2
KMS-11	GDSC1; CTRP2	-2.3829	1.1522	-2.3999	56.0231
P3HR-1	CTRP2	-2.3601	4.6827	-2.795	54.9302
MHH-PREB-1	GDSC1	-2.3576	-1.0355	-2.3581	45.4885
KMS-20	CTRP2	-2.3333	-1.2645	-2.3333	55.8133
Sc-1	GDSC1	-2.3013	0.2834	-2.3466	45.0691
RPMI-8866	GDSC1	-2.2841	-1.0923	-2.299	29.0728
Karpas-422	GDSC1; CTRP2	-2.2652	-0.3356	-2.2654	55.3574
HAL-01	GDSC1	-2.2648	-0.0499	-2.2858	44.653
Ci-1	CTRP2	-2.248	-1.7188	-2.248	55.2449
Pfeiffer	CTRP2	-2.2156	-1.5205	-2.2156	55.0291
PL21	CTRP2	-2.1724	-0.5333	-2.1725	54.7413
SU-DHL-4	GDSC1; CTRP2	-2.1495	-0.337	-2.1496	54.5877
Karpas-1106P	GDSC1	-2.11	-1.0409	-2.1101	55.3961
SET-2	CTRP2	-2.0865	0.5407	-2.0892	54.153
BL-70	CTRP2	-2.0497	-0.0548	-2.05	53.9219
KO52	CTRP2	-1.9799	-1.1658	-1.9799	53.4593
HD-MY-Z	CTRP2	-1.977	2.7247	-2.0755	53.2377
KCL-22	GDSC1; CTRP2	-1.9602	0.6387	-1.9629	53.3156
Mono-Mac-6	GDSC1; CTRP2	-1.9467	3.8377	-2.1883	52.8822
MEG-01	GDSC1	-1.8884	1.1626	-2.0163	41.3932
GR-ST	GDSC1	-1.7865	0.5959	-1.8345	40.1357
HuT 78	CTRP2	-1.7447	3.5279	-1.9246	51.7327
L-428	GDSC1; CTRP2	-1.7268	1.2441	-1.7354	51.7589
MHH-CALL-2	GDSC1	-1.7007	-0.1465	-1.7055	50.2812
Ramos.2G6.4C10	GDSC1	-1.6725	-0.1694	-1.6765	38.846
GDM-1	GDSC1; CTRP2	-1.6532	1.0834	-1.6583	51.276
K-562	GDSC1; CTRP2	-1.5856	0.9887	-1.589	50.8291
TK [Human B-cell lymphoma]	GDSC1	-1.5386	-0.2836	-1.5399	37.5322
P31/FUJ	GDSC1; CTRP2	-1.5319	0.6178	-1.5328	50.4742
HDLM-2	GDSC1; CTRP2	-1.5272	0.9579	-1.53	50.4417
U266B1	GDSC1; CTRP2	-1.5178	1.506	-1.5291	50.3772
HT	GDSC1; CTRP2	-1.5012	0.5508	-1.5018	50.2699
KMOE-2	GDSC1	-1.4706	1.096	-1.5581	37.2544
CMK	GDSC1; CTRP2	-1.4236	0.7639	-1.4247	49.7532
NK-92MI	GDSC1	-1.4092	0.5851	-1.7196	20.1397
KG-1	GDSC1	-1.384	1.1383	-1.9101	21.3427
JJN-3	GDSC1; CTRP2	-1.2977	0.1704	-1.2977	48.9141
LAMA-84	GDSC1; CTRP2	-1.1453	1.6486	-1.1541	47.9101
OCI-Ly7	GDSC1	-1.0994	0.6639	-1.1217	42.8737
OPM-2	GDSC1; CTRP2	-1.0817	1.4359	-1.0863	47.4827
TALL-1 [Human adult T-ALL]	CTRP2	-1.0754	19.8147	-7.4043	49.0366
Toledo	CTRP2	-1.0687	7.7217	-2.2335	48.0831
Karpas-620	GDSC1; CTRP2	-1.0648	2.6527	-1.1147	47.4249
KMS-18	CTRP2	-0.9735	1.6512	-0.9802	46.7665
EJM	GDSC1; CTRP2	-0.9299	0.9189	-0.9303	46.4645
F-36P	CTRP2	-0.8434	1.7884	-0.851	45.904
DG-75	GDSC1	-0.7571	1.5356	-0.8609	30.436
MN-60	GDSC1	-0.7568	2.1338	-0.9886	31.0491
PL-21	GDSC1	-0.6885	2.844	-1.1195	31.3289
JeKo-1	GDSC1; CTRP2	-0.4168	2.1857	-0.4268	43.073
L-1236	GDSC1; CTRP2	-0.2877	2.3583	-0.3002	42.2209
YT	GDSC1	-0.1494	2.8213	-0.5263	25.941
ME1	CTRP2	-0.1426	2.2156	-0.1493	41.2393
TF-1	CTRP2	0.0163	4.7288	-0.2273	40.7793
RC-K8	GDSC1	0.0502	3.4285	-0.5278	25.0725
KY821	GDSC1	0.1235	2.2066	-0.0468	22.2322
KMM-1	CTRP2	0.4397	6.5024	-0.2031	39.0067
Karpas-45	GDSC1	0.518	3.5919	-0.0958	20.8111
ROS-50	GDSC1	0.6646	3.5751	0.0651	19.3311
LP-1	GDSC1; CTRP2	0.9675	2.7319	0.9646	33.8327
SK-MM-2	GDSC1; CTRP2	1.1689	5.0382	0.9607	33.1582
ME1	GDSC1	2.6409	5.6656	0.9079	7.8085
REC-1	CTRP2	3.5481	8.9935	2.189	21.6653

Cancer Drug Sensitivity Data Curated from 28 Cell Line(s) in Oesophagus Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
TE8	CTRP2	-2.9698	2.9643	-3.1551	58.8269
TE15	CTRP2	-2.8735	2.5191	-2.9999	58.5269
KYSE-270	GDSC1	-7.0294	-2.1818	-7.0921	80.412
TE-8	GDSC1	-6.2682	-0.925	-6.4064	74.6348
TE-15	GDSC1	-4.9197	-1.8337	-4.9358	68.9918
KYSE-510	GDSC1; CTRP2	-4.8501	-3.315	-4.8501	72.568
KYSE-450	GDSC1; CTRP2	-3.8578	-1.5078	-3.858	65.9106
KYSE-180	GDSC1; CTRP2	-3.6753	-0.6478	-3.6777	64.5669
TE-5	GDSC1; CTRP2	-3.5205	1.4009	-3.5822	62.6721
TE-1	GDSC1; CTRP2	-3.4262	0.1998	-3.4368	62.7533
TE-4	GDSC1; CTRP2	-2.8663	2.8849	-3.0348	58.3159
TE-10	GDSC1; CTRP2	-2.5308	2.123	-2.6034	56.7126
TE-9	GDSC1; CTRP2	-2.4647	0.7562	-2.4735	56.6032
T.T	GDSC1	-2.3361	0.3335	-2.3876	45.4164
TE-11	GDSC1; CTRP2	-1.7584	1.472	-1.7729	51.959
OE21	GDSC1; CTRP2	-1.5842	2.247	-1.6276	50.801
KYSE-70	GDSC1; CTRP2	-1.5291	3.0841	-1.6401	50.431
COLO 680N	GDSC1; CTRP2	-1.2503	5.0433	-1.6673	48.7889
OE19	GDSC1; CTRP2	-1.22	5.4817	-1.9164	45.6868
EC-GI-10	GDSC1; CTRP2	-0.8457	4.1079	-1.0486	46.1896
TE-6	GDSC1; CTRP2	-0.7376	4.3875	-0.9794	45.5591
KYSE-520	GDSC1; CTRP2	-0.7316	7.4207	-1.7674	46.2828
KYSE-140	GDSC1; CTRP2	-0.7248	5.1021	-1.1087	45.6494
KYSE-410	GDSC1; CTRP2	-0.6972	6.5586	-1.4595	45.87
OE33	GDSC1; CTRP2	-0.5816	2.8635	-0.666	40.4084
TE-14	CTRP2	-0.1072	1.9054	-0.1094	40.9897
KYSE-150	GDSC1; CTRP2	1.2901	9.4578	-0.3549	36.2333
KYSE-30	CTRP2	4.1138	10.1964	2.2008	20.151

Cancer Drug Sensitivity Data Curated from 40 Cell Line(s) in Pancreas Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
N2a-PK1	CTRP2	0.9787	4.9516	0.6323	30.2623
MZ-PC-1	GDSC1	-4.7314	0.6614	-4.9941	64.2119
Panc 03.27	GDSC1; CTRP2	-4.4644	-0.3738	-4.4775	68.9961
MIA PaCa-2	GDSC1; CTRP2	-4.0838	-0.9018	-4.0864	67.1582
KP-4	GDSC1; CTRP2	-3.8779	-1.3545	-3.8783	66.0144
HuP-T4	GDSC1; CTRP2	-3.5444	-0.2038	-3.5499	63.6179
PaTu 8988t	GDSC1; CTRP2	-3.5201	-0.5731	-3.5223	63.5746
KP-1N	GDSC1	-3.1697	0.3302	-3.268	53.121
PSN1	GDSC1; CTRP2	-2.8769	3.4604	-3.1273	58.0907
L3.3	CTRP2	-2.7464	-1.013	-2.7465	58.5639
PL4	GDSC1	-2.0947	2.4596	-2.5363	44.0393
BxPC-3	GDSC1; CTRP2	-1.6278	1.495	-1.6407	51.1023
SU.86.86	GDSC1; CTRP2	-1.3974	3.6703	-1.5736	49.6097
Capan-1	GDSC1; CTRP2	-1.1471	9.7909	-3.0706	48.6684
SW1990	GDSC1; CTRP2	-0.9301	5.7909	-1.4994	47.027
Panc 10.05	GDSC1; CTRP2	-0.6658	6.6361	-1.4484	45.7136
HuP-T3	GDSC1; CTRP2	-0.5272	7.0449	-1.4236	45.0579
CFPAC-1	GDSC1; CTRP2	-0.4823	5.3432	-0.8999	44.2217
YAPC	GDSC1; CTRP2	-0.3631	3.5968	-0.4632	42.9246
Panc 08.13	GDSC1; CTRP2	-0.1877	1.9306	-0.1907	41.5286
HPAF-II	GDSC1; CTRP2	-0.0896	6.0948	-0.6636	42.0908
KP-3	GDSC1; CTRP2	0.1074	5.9014	-0.3963	40.7569
PK-59	CTRP2	0.2683	8.2141	-0.9611	41.1176
QGP-1	GDSC1; CTRP2	0.3429	5.2957	0.0095	38.896
KP-2	GDSC1; CTRP2	0.5504	8.561	-0.787	39.7398
HPAC	GDSC1; CTRP2	0.5589	8.3053	-0.6823	39.5161
DAN-G	GDSC1; CTRP2	0.564	2.432	0.5613	36.5198
SNU-410	CTRP2	0.7064	5.4072	0.3796	36.5383
SNU-213	CTRP2	0.7573	3.2424	0.7364	35.2919
SUIT-2	GDSC1; CTRP2	1.1812	8.4102	-0.0551	35.9214
Panc 05.04	CTRP2	1.3078	10.3568	-0.7124	36.9268
Hs 766T	GDSC1; CTRP2	1.7287	5.5255	1.4654	29.6384
Panc 04.03	GDSC1; CTRP2	1.7492	8.2227	0.6232	32.212
PaTu 8988s	CTRP2	1.9307	8.5998	0.6683	31.4948
AsPC-1	GDSC1; CTRP2	2.1783	8.3862	1.0158	29.6635
TCC-Pan2	CTRP2	2.5707	9.3971	1.0077	28.4976
Capan-2	GDSC1; CTRP2	3.1034	9.2741	1.6102	24.9682
Panc 02.03	GDSC1; CTRP2	3.5847	10.864	1.369	24.4852
PK-45H	CTRP2	3.7082	9.6555	1.5486	18.5648
PaTu 8902	GDSC1; CTRP2	4.6775	17.6505	-0.9338	28.3614

Cancer Drug Sensitivity Data Curated from 77 Cell Line(s) in Skin Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
SH4	CTRP2	0.9654	4.0318	0.8229	29.628
CHL-1	GDSC1	-5.2765	-2.2031	-5.2887	72.0629
Mel JuSo	GDSC1; CTRP2	-5.214	0.0332	-5.2564	72.1428
MZ-MEL-2	GDSC1	-5.1439	-0.7709	-5.2352	68.8231
COLO 679	GDSC1	-5.1307	-1.2612	-5.1811	69.569
A-431	GDSC1	-4.9554	-1.3822	-4.992	68.6111
HMV-II	GDSC1	-4.8571	0.6338	-5.1248	64.9661
IST-MEL1	GDSC1	-4.8507	0.8088	-5.1506	64.6827
G-mel	GDSC1	-4.6944	-1.2805	-4.728	66.6299
A2058	GDSC1; CTRP2	-4.6773	-1.6818	-4.6784	71.0504
WM793	GDSC1; CTRP2	-4.6298	-0.0137	-4.6557	69.5267
A-388	GDSC1	-4.5543	0.5687	-4.7867	63.2772
A-375	GDSC1; CTRP2	-4.4475	-1.9328	-4.4478	69.7538
Mel Ho	GDSC1; CTRP2	-4.4392	-1.475	-4.4404	69.539
G-361	GDSC1; CTRP2	-4.2018	-0.2554	-4.2137	67.4866
SK-MEL-30	GDSC1; CTRP2	-4.1212	-1.3375	-4.122	67.5448
Hs 944.T	CTRP2	-4.0882	1.2197	-4.16	65.7391
HT-144	GDSC1; CTRP2	-3.8623	-0.4691	-3.8674	65.6458
A101D	GDSC1; CTRP2	-3.8409	-0.0693	-3.8517	65.3301
MZ-MEL-7	GDSC1	-3.5169	0.7836	-3.7057	55.8297
WM278	GDSC1	-3.5136	0.8278	-3.7096	55.781
IPC-298	GDSC1; CTRP2	-3.3476	-0.2331	-3.3514	62.4059
IGR-37	GDSC1; CTRP2	-3.3257	-0.5686	-3.3272	62.337
SH-4	GDSC1	-3.3168	1.3479	-3.5958	54.0211
DJM-1	GDSC1	-3.3045	0.3906	-3.419	54.2649
IGR-1	GDSC1; CTRP2	-3.1059	-0.0182	-3.1101	60.8311
WM35	GDSC1	-3.011	0.5614	-3.1289	51.6882
RPMI-7951	GDSC1; CTRP2	-2.9198	-0.581	-2.9203	59.6981
MMAc-SF	GDSC1	-2.8418	0.4658	-2.9362	50.1807
WM115	GDSC1; CTRP2	-2.6787	1.5783	-2.7211	57.7632
Hs 852.T	CTRP2	-2.4158	1.6026	-2.4512	56.1471
Hs 938.T	GDSC1	-2.401	1.2009	-2.5752	46.2517
451Lu	GDSC1	-2.3898	0.3417	-2.4447	45.9337
COLO 800	GDSC1; CTRP2	-2.1098	1.1651	-2.1223	54.2668
Hs 294T	CTRP2	-2.0749	0.0726	-2.0754	54.0881
GAK	GDSC1	-2.0726	0.7315	-2.1516	42.9842
RVH-421	GDSC1; CTRP2	-2.0343	2.0208	-2.0801	53.6906
Hs 936.T	CTRP2	-2.0189	1.9068	-2.0577	53.6075
SK-MEL-2	GDSC1; CTRP2	-1.9888	-0.4429	-1.9888	53.5178
WM1552C	GDSC1	-1.9863	4.4667	-3.1003	44.2992
WM266-4	CTRP2	-1.9662	-0.336	-1.9662	53.3675
LB373-MEL-D	GDSC1	-1.901	4.9722	-3.2077	43.97
LOX-IMVI	GDSC1; CTRP2	-1.7731	1.215	-1.7817	52.0644
Hs 940.T	GDSC1; CTRP2	-1.7645	3.5753	-1.9526	51.8473
WM88	CTRP2	-1.5603	1.5172	-1.5725	50.6572
UACC-62	GDSC1; CTRP2	-1.5271	0.5335	-1.5277	50.4422
SK-MEL-5	GDSC1; CTRP2	-1.5011	0.7334	-1.5023	50.269
SK-MEL-3	GDSC1; CTRP2	-1.4418	1.4494	-1.4507	49.8752
UACC-257	GDSC1; CTRP2	-1.2905	2.072	-1.3156	48.8827
M14	GDSC1	-1.2179	2.666	-1.6404	36.2103
IGR-39	CTRP2	-0.9795	3.7284	-1.1353	46.9833
CJM [Human melanoma]	CTRP2	-0.9585	2.022	-0.974	46.6813
COLO 829	GDSC1; CTRP2	-0.9362	3.6271	-1.0755	46.6911
Malme-3M	CTRP2	-0.8821	1.1883	-0.8833	46.1484
K029AX	CTRP2	-0.8635	2.0892	-0.8962	42.2629
WM1799	CTRP2	-0.6808	4.4433	-0.928	45.2107
VMRC-MELG	GDSC1	-0.5679	0.7618	-0.578	28.1395
LB2518-MEL	GDSC1	-0.4413	4.6167	-1.5264	31.9132
CP50-MEL-B	GDSC1	-0.4155	1.9418	-0.5709	27.3823
SK-MEL-24	GDSC1; CTRP2	-0.2734	4.599	-0.5164	42.6313
CP66-MEL	GDSC1	-0.0697	2.4895	-0.3357	24.6009
MeWo	GDSC1; CTRP2	-0.0538	2.2013	-0.0592	40.6439
WM983B	CTRP2	-0.0346	3.6429	-0.121	40.7371
HMCB	CTRP2	-0.0243	2.5696	-0.0381	40.4727
COLO 783	GDSC1	0.1227	1.9344	0.0155	21.9147
COLO 792	GDSC1; CTRP2	0.1429	2.0554	0.1409	39.3229
SK-MEL-28	GDSC1; CTRP2	0.1675	0.9834	0.1675	39.1526
SK-MEL-1	GDSC1; CTRP2	0.2078	2.0671	0.2061	38.8897
SK-MEL-31	GDSC1; CTRP2	0.4699	3.653	0.4094	37.3277
Hs 839.T	CTRP2	0.5133	4.7823	0.3	37.481
WT2-iPS	GDSC1	1.2911	6.457	-0.657	20.9541
COLO 741	CTRP2	1.4125	2.2454	1.4125	30.8585
MDA-MB-435S	CTRP2	1.8028	5.8104	1.4772	29.358
Hs 895.T	CTRP2	2.2598	9.619	0.5905	30.6919
Hs 688(A).T	CTRP2	3.7416	8.2171	2.7269	19.1119
Hs 934.T	CTRP2	5.2788	17.8961	-0.5309	26.0776
EquiPSC Line K2	GDSC1	-2.009	3.0911	-2.635	43.6751

Cancer Drug Sensitivity Data Curated from 11 Cell Line(s) in Aero Dig Tract Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
HCE-4	GDSC1	-5.5124	-2.0788	-5.5331	73.382
KYSE-220	GDSC1	-3.7356	-1.0238	-3.7537	58.5861
KYSE-50	GDSC1	-3.4288	-0.44	-3.4679	55.6277
OACP4 C	GDSC1	-3.3093	1.0718	-3.533	65.1962
TE-12	GDSC1	-2.7539	4.7326	-4.022	49.5783
FLO-1	GDSC1	-2.6189	2.5044	-3.121	58.117
ESO-26	GDSC1	-2.2961	1.1258	-2.4489	56.602
KYAE-1	GDSC1	-2.1847	0.5514	-2.2497	55.83
SK-GT-4	GDSC1	-1.272	5.1853	-2.6325	46.9987
ESO-51	GDSC1	-1.2228	4.9566	-2.4861	46.525
OACM5.1 C	GDSC1	0.6933	6.5734	-1.2773	31.933

Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Ascites Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
COLO 684	GDSC1; CTRP2	-1.2937	3.1777	-1.4013	48.9417

Cancer Drug Sensitivity Data Curated from 34 Cell Line(s) in Autonomic Ganglia Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
IMR-32	CTRP2	-6.3924	-5.9795	-6.3924	82.8558
NH-6	CTRP2	-6.212	-4.4422	-6.212	81.481
KP-N-SI9s	CTRP2	-5.2304	-1.497	-5.2349	73.9378
CHP-212	GDSC1; CTRP2	-4.9992	-1.751	-5.0009	72.9284
IMR-5	GDSC1	-4.8425	-3.3313	-4.8425	69.57
GI-ME-N	GDSC1	-4.69	0.5699	-4.9331	64.0933
NB1	GDSC1; CTRP2	-4.4723	-0.1614	-4.4906	68.8644
SK-N-MC-IXC	GDSC1	-4.3491	-3.521	-4.3491	64.8441
MHH-NB-11	GDSC1; CTRP2	-4.3101	-1.4216	-4.3111	68.7366
CHP-126	GDSC1; CTRP2	-4.0659	-0.3644	-4.0743	66.7881
NB69	GDSC1	-3.913	-0.2	-3.9954	59.5823
SK-N-SH	GDSC1; CTRP2	-3.6441	-0.9772	-3.6449	64.4487
Kelly	GDSC1; CTRP2	-3.5863	-0.0805	-3.5939	63.8273
NH-12	GDSC1	-3.3563	0.2926	-3.4616	54.7382
SJNB-13	GDSC1	-3.2339	1.0473	-3.4469	53.468
SJNB-10	GDSC1	-2.9368	0.5897	-3.0537	51.0296
SJNB-7	GDSC1	-2.2624	0.713	-2.3512	44.8061
SJNB-14	GDSC1	-2.2262	0.8436	-2.33	44.5017
NB(TU)1	GDSC1	-2.2076	0.7693	-2.3001	44.2993
KP-N-YS	GDSC1	-2.1456	0.6303	-2.5306	29.6797
GOTO	GDSC1	-1.9399	0.9742	-2.0425	41.7982
SJNB-5	GDSC1	-1.8754	1.5793	-2.0795	41.5092
SK-N-DZ	GDSC1; CTRP2	-1.8731	3.1786	-2.0155	52.5445
SK-N-BE(2)	CTRP2	-1.7492	1.8791	-1.7784	51.8814
SJNB-12	GDSC1	-1.7316	3.3102	-2.4063	41.4936
SiMa	GDSC1	-1.4388	1.8806	-1.6707	37.5321
SK-N-AS	GDSC1; CTRP2	-1.4176	1.8364	-1.4367	49.7168
LA-N-6	GDSC1	-1.3718	2.4434	-1.743	37.4302
SJNB-17	GDSC1	-1.108	7.1116	-3.3059	46.5214
SK-N-BE(2)-M17	GDSC1	-0.7515	2.6702	-1.1334	31.6977
KP-N-YN	GDSC1; CTRP2	-0.068	2.4005	-0.0777	40.7513
SK-N-FI	GDSC1; CTRP2	0.6897	3.368	0.6599	35.7708
TGW	GDSC1	1.3386	6.2854	-0.529	20.1177
SJNB-6	GDSC1	2.2561	9.6563	-1.4003	21.4765

Cancer Drug Sensitivity Data Curated from 7 Cell Line(s) in Biliary Tract Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
SNU-478	CTRP2	-3.3601	-0.2598	-3.3637	62.491
SNU-1079	CTRP2	-1.3607	1.6719	-1.3735	49.3395
HuH-28	CTRP2	-1.2162	1.7056	-1.2275	48.383
HuCC-T1	GDSC1; CTRP2	-0.4907	9.268	-2.169	45.5606
SNU-1196	CTRP2	0.2279	3.858	0.1329	39.0291
SNU-308	CTRP2	0.793	3.59	0.7526	35.1173
SNU-869	CTRP2	1.5603	5.563	1.2734	30.8295

Cancer Drug Sensitivity Data Curated from 89 Cell Line(s) in Breast Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
DU4475	GDSC1; CTRP2	-7.2066	-3.614	-7.2076	85.0872
OCUB-M	GDSC1	-6.2002	-3.1451	-6.2063	79.5217
CAL-51	GDSC1; CTRP2	-5.237	-2.5431	-5.2372	74.7777
CAL-148	GDSC1; CTRP2	-4.9745	-2.2748	-4.9748	73.0984
MRK-nu-1	GDSC1	-4.1785	0.6133	-4.3893	60.7968
HCC1599	GDSC1	-3.9185	-2.2567	-3.9188	60.6257
MDA-MB-468	GDSC1; CTRP2	-3.6638	-0.5104	-3.6671	64.4536
HCC2157	GDSC1	-3.4173	3.4882	-4.2947	53.8951
HCC1806	GDSC1; CTRP2	-3.4156	-1.0962	-3.4158	62.988
HCC1569	GDSC1	-2.6916	2.436	-3.181	48.9848
CAL-85-1	GDSC1; CTRP2	-2.5715	5.2823	-3.1618	55.7672
AU565	GDSC1; CTRP2	-2.3784	1.0192	-2.3917	56.0138
HCC38	GDSC1; CTRP2	-2.3077	2.6353	-2.415	55.2472
HMC-1-8	CTRP2	-2.0118	1.1113	-2.0216	53.6336
MDA-MB-157	GDSC1; CTRP2	-1.9635	1.7398	-1.9923	53.2713
MCF-7	GDSC1; CTRP2	-1.9416	7.1817	-3.0062	52.2996
SK-BR-3	CTRP2	-1.8643	0.488	-1.8656	52.6838
HCC1954	GDSC1; CTRP2	-1.6274	1.8176	-1.6507	51.0919
HCC70	GDSC1	-1.3275	1.8028	-1.532	36.3728
MDA-MB-330	GDSC1	-1.3233	1.6348	-1.4919	36.1842
EFM-192A	GDSC1; CTRP2	-1.2266	2.2187	-1.2567	48.4662
UACC-893	GDSC1	-1.0731	1.022	-1.1258	33.254
EFM-19	GDSC1	-1.0539	4.3208	-2.0508	36.7801
HCC1500	GDSC1; CTRP2	-0.9757	2.8865	-1.0393	46.8588
HCC1187	GDSC1	-0.8676	0.7755	-0.8883	31.1043
CAL-120	GDSC1	-0.7986	2.863	-1.2453	32.4306
HCC2218	GDSC1; CTRP2	-0.7981	3.1192	-0.8732	45.7175
HCC1143	GDSC1; CTRP2	-0.7013	3.9362	-0.8673	45.2271
ZR-75-1	CTRP2	-0.6925	5.0533	-1.0628	45.4378
Evsa-T	GDSC1	-0.6025	0.7687	-0.614	28.4825
BT-474	GDSC1; CTRP2	-0.5252	1.5004	-0.5266	43.7716
MDA-MB-453	GDSC1; CTRP2	-0.5155	1.3605	-0.5163	43.7054
T-47D	GDSC1; CTRP2	-0.486	4.4781	-0.7241	43.9716
BT-549	GDSC1; CTRP2	-0.3968	2.77	-0.4294	42.9964
Hs 578T	GDSC1; CTRP2	-0.3746	2.5345	-0.3952	42.8195
CAMA-1	GDSC1; CTRP2	-0.3364	2.9261	-0.3762	42.6136
MDA-MB-436	GDSC1	-0.1355	3.8264	-0.8808	27.6546
MDA-MB-175-VII	GDSC1	0.2589	4.3789	-0.6977	25.0639
MFM-223	GDSC1	0.3235	1.4527	0.3029	19.5265
BT-20	GDSC1; CTRP2	0.3614	3.4732	0.3111	38.0171
ZR-75-30	GDSC1; CTRP2	0.4737	5.7366	0.0461	38.2937
MDA-MB-231	GDSC1; CTRP2	0.622	4.9089	0.3936	36.8128
HCC1395	GDSC1; CTRP2	0.6398	6.5813	-0.0088	37.7868
COLO 824	GDSC1	0.6417	4.1207	-0.1911	20.8391
HCC202	GDSC1; CTRP2	0.7671	4.7046	0.4647	31.5989
HCC1937	GDSC1; CTRP2	0.7966	8.8251	-0.6251	38.528
MDA-MB-415	GDSC1	0.841	4.4665	-0.1427	19.8018
HCC1428	GDSC1; CTRP2	0.8702	3.4586	0.8414	34.5657
UACC-812	GDSC1	0.8799	3.4115	-1.0123	5.6399
HDQ-P1	GDSC1; CTRP2	1.3115	7.4619	0.4329	34.2182
HCC1419	GDSC1; CTRP2	1.4	5.268	1.1647	31.7192
MDA-MB-361	GDSC1; CTRP2	1.5563	6.7829	0.9265	31.9476
BT-483	GDSC1	1.9176	6.9598	-0.342	17.2144
JIMT-1	GDSC1; CTRP2	2.9143	9.2981	1.4053	26.2036
Hs 578Bst	CTRP2	3.8568	14.3038	-0.0251	28.0076
KPL-1	CTRP2	5.3154	5.8894	5.2852	4.9602
BT 239	CTRP2	-6.0968	-4.375	-6.0968	80.7536
BT164	CTRP2	-4.7336	-1.0836	-4.7386	70.9874
BT 145	CTRP2	-4.6009	-1.0825	-4.6051	70.2578
BT 286	CTRP2	-4.5025	6.1556	-5.4963	62.9065
BT 271	CTRP2	-4.3901	6.6574	-5.5162	62.1464
BT 112	CTRP2	-3.1444	0.0879	-3.1501	61.0505
BT 504	CTRP2	-3.0967	-0.1117	-3.0999	60.7903
BT 428	CTRP2	-2.5657	0.8253	-2.5773	57.239
BT 131	CTRP2	-2.0611	5.7805	-2.7307	53.1264
BT 245	CTRP2	-1.8154	0.1329	-1.8157	52.3622
BT 228	CTRP2	-1.659	1.8127	-1.6829	51.2985
BT 440	CTRP2	-1.6052	1.8995	-1.6314	50.9456
BT 139	CTRP2	-1.4414	1.8949	-1.4632	49.8732
BT 416	CTRP2	-1.2488	-0.0506	-1.2488	48.5882
BT147	CTRP2	-1.0004	7.2787	-2.0131	47.6709
BT 482	CTRP2	-0.9755	1.4841	-0.9797	46.7756
BT 231	CTRP2	-0.8662	1.8964	-0.8765	46.0605
BT 333	CTRP2	-0.4539	5.6077	-0.933	44.1363
BT 330	CTRP2	-0.3702	7.4725	-1.3923	44.3337
BT 248	CTRP2	-0.2374	7.4558	-1.2426	43.5854
BT 159	CTRP2	-0.1756	2.2031	-0.1825	41.4592
BT 172	CTRP2	0.3409	8.7969	-1.1007	41.0589
BT 179	CTRP2	0.4279	2.904	0.4126	37.4671
BT 187	CTRP2	0.4705	6.8969	-0.2911	39.0772
BT 359	CTRP2	0.7383	6.9702	-0.0232	37.4488
BT 422	CTRP2	0.8103	4.7065	0.6341	35.4243
BT 224	CTRP2	1.2084	6.2263	0.4847	29.9779
BT 328	CTRP2	1.5483	7.7134	0.5986	32.9477
BT 498	CTRP2	1.9437	6.9325	1.2986	29.4973
BT 216	CTRP2	2.24	9.7267	0.5238	30.9434
BT 444	CTRP2	2.3079	8.5919	1.0702	29.0922
BT 320	CTRP2	4.3087	10.3328	2.3247	19.199
BT 232	CTRP2	4.528	14.781	0.3559	25.3296

Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Tongue Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
YD-38	CTRP2	-1.4665	0.5739	-1.467	50.0384

Cancer Drug Sensitivity Data Curated from 68 Cell Line(s) in Central Nervous System Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
KS-1 [Human Krukenberg tumour]	GDSC1	-7.643	2.1786	-8.5143	72.7263
Daoy	GDSC1; CTRP2	-5.5307	-2.5252	-5.5313	76.4059
8-MG-BA	GDSC1; CTRP2	-4.9016	-2.4637	-4.9017	72.7369
M059J	GDSC1	-4.799	-2.0946	-4.8066	68.3749
ONS-76	GDSC1; CTRP2	-4.5742	-0.9729	-4.5792	70.0347
MOG-G-UVW	GDSC1	-4.3869	-1.6567	-4.3981	64.6069
SK-MG-1	GDSC1	-4.368	-1.6	-4.3804	64.4044
H4	GDSC1	-4.1106	-0.1726	-4.207	61.0832
GI-1	GDSC1	-3.902	-1.007	-3.9252	60.0391
D-566MG	GDSC1	-3.7456	-1.5484	-3.7503	58.8595
U-251MG	GDSC1; CTRP2	-3.713	-1.0214	-3.7139	64.897
YKG-1	GDSC1; CTRP2	-3.6223	1.8613	-3.724	62.8958
A-172	GDSC1; CTRP2	-3.4744	-0.1105	-3.4805	63.1574
KNS-60	CTRP2	-3.1733	2.6165	-3.3281	60.0852
SNU-466	CTRP2	-3.1649	-1.7644	-3.1649	61.3529
SF268	GDSC1; CTRP2	-3.13	0.7402	-3.1492	60.7658
D-423MG	GDSC1	-3.1237	-0.5435	-3.1463	52.8602
KNS-81-FD	GDSC1	-2.9465	2.8707	-3.5864	50.9073
KALS-1	GDSC1; CTRP2	-2.8695	5.5907	-3.5635	57.0115
SF539	GDSC1; CTRP2	-2.8069	0.6576	-2.8183	58.7975
D-263MG	GDSC1	-2.7469	1.7982	-3.0761	49.3829
Onda 10	GDSC1	-2.7268	0.9617	-2.885	49.1575
LN-18	GDSC1; CTRP2	-2.5265	1.5427	-2.5623	56.8448
SW1783	GDSC1; CTRP2	-2.41	3.1806	-2.5871	55.6825
D283 Med	GDSC1; CTRP2	-2.3505	-0.0926	-2.351	55.9187
MOG-G-CCM	GDSC1	-2.3143	2.5315	-2.7965	45.9444
LN-229	GDSC1; CTRP2	-2.2281	0.7677	-2.2344	55.0692
SNB-75	GDSC1; CTRP2	-2.1632	3.1653	-2.3222	54.2695
LNZTA3WT4	GDSC1	-2.0741	1.1443	-2.213	43.1688
Hs 683	GDSC1; CTRP2	-2.0643	3.1732	-2.2181	53.6875
NMC-G1	GDSC1; CTRP2	-2.0367	7.1253	-3.092	52.7466
SF126	GDSC1; CTRP2	-1.9359	3.3028	-2.0981	52.9039
D-336MG	GDSC1	-1.8696	2.3335	-2.2556	51.8672
Onda 11	GDSC1	-1.8083	3.2318	-2.4632	42.0842
D-247MG	GDSC1	-1.6843	8.0792	-4.3253	50.0328
PFSK-1	GDSC1	-1.6778	0.6644	-1.7267	39.0911
U-87MG ATCC	GDSC1; CTRP2	-1.6456	1.8199	-1.6695	51.2111
CAS-1	GDSC1; CTRP2	-1.5956	4.5541	-1.9389	50.7838
42-MG-BA	GDSC1; CTRP2	-1.5528	1.1063	-1.5574	50.6115
AM-38	GDSC1; CTRP2	-1.4263	3.3001	-1.5558	49.7845
D-392MG	GDSC1	-1.3371	2.6848	-1.776	37.358
SNU-626	CTRP2	-1.053	2.3579	-1.0848	47.3275
DK-MG	GDSC1; CTRP2	-0.9929	3.3111	-1.0978	47.0167
KINGS-1	GDSC1	-0.6721	1.3928	-0.7467	29.4688
GaMG	GDSC1; CTRP2	-0.5005	5.2245	-0.8922	44.296
YH-13	GDSC1; CTRP2	-0.4719	5.0649	-0.8255	44.0645
D-542MG	GDSC1	-0.3466	4.8455	-1.525	31.4769
D-502MG	GDSC1	-0.2951	0.904	-0.3041	25.4825
M059K	CTRP2	-0.2471	2.4755	-0.2625	41.9592
SNU-489	CTRP2	-0.1231	2.2054	-0.1293	41.1077
LN-405	GDSC1	0.1698	4.0944	-0.6691	25.2892
SW1088	GDSC1; CTRP2	0.1876	6.9529	-0.6166	40.8488
U-118MG	GDSC1; CTRP2	0.2674	6.9223	-0.5201	40.3452
GB-1	GDSC1; CTRP2	0.3439	5.041	0.0657	38.7527
KNS-81	CTRP2	0.3505	12.3929	-2.5824	42.8677
CCF-STTG1	CTRP2	0.8156	5.7458	0.4168	36.0323
SF295	GDSC1; CTRP2	0.8686	8.3886	-0.3813	37.7703
SNU-1105	CTRP2	0.9802	3.2504	0.9649	33.7893
KNS-42	GDSC1; CTRP2	0.9873	9.2436	-0.5877	37.7723
Becker	GDSC1; CTRP2	1.2186	6.6581	0.5983	34.0781
GOS-3	CTRP2	1.3861	12.1781	-1.4314	37.9943
SNU-738	CTRP2	1.8035	5.9616	1.4385	29.4856
SNU-201	CTRP2	2.0376	8.9737	0.6297	31.2676
TM-31	CTRP2	2.1841	8.5069	0.9737	29.7768
DBTRG-05MG	GDSC1; CTRP2	2.3999	18.2688	-3.319	37.9433
GMS-10	CTRP2	2.4815	11.8176	-0.1661	32.0563
T98G	GDSC1; CTRP2	3.2357	9.6845	1.563	24.7634
KG-1-C	CTRP2	5.3737	6.201	5.2644	4.8585

Cancer Drug Sensitivity Data Curated from 3 Cell Line(s) in Digestive System Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
ETK-1	GDSC1	-3.0251	1.7632	-3.3709	51.6342
TGBC1TKB	GDSC1	-0.3237	3.5216	-0.9631	28.8916
TGBC24TKB	GDSC1	1.0882	6.5168	-0.8753	22.7758

Cancer Drug Sensitivity Data Curated from 23 Cell Line(s) in Endometrium Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
JHUEM-2	CTRP2	-5.8845	-3.2051	-5.8846	78.8477
ESS-1	GDSC1; CTRP2	-5.8268	-3.6731	-5.8268	78.8274
JHUEM-7	CTRP2	-3.1861	0.401	-3.1975	61.2219
AN3-CA	GDSC1; CTRP2	-2.9051	1.7406	-2.9656	59.0462
HEC-151	CTRP2	-2.8734	-0.2172	-2.8749	59.3648
MFE-296	GDSC1; CTRP2	-2.7845	-0.013	-2.7868	58.7647
JHUEM-1	CTRP2	-2.2164	-0.1867	-2.2166	55.0313
RL95-2	GDSC1; CTRP2	-1.701	1.6677	-1.7205	51.5769
HEC-108	CTRP2	-1.3432	1.6946	-1.3564	49.2242
HEC-265	CTRP2	-1.228	-0.1165	-1.228	48.4496
MFE-319	GDSC1; CTRP2	-1.1655	2.969	-1.2454	48.1053
HEC-59	CTRP2	-0.9903	1.1802	-0.9919	46.8691
HEC-6	CTRP2	-0.8327	2.0964	-0.848	45.8473
JHUEM-3	CTRP2	-0.8106	6.8414	-1.6686	46.5722
KLE	GDSC1; CTRP2	-0.4426	5.4658	-0.8858	44.0172
EN	GDSC1; CTRP2	-0.1335	2.694	-0.1545	41.2191
HEC-251	CTRP2	-0.0498	7.0489	-0.9055	42.3179
MFE-280	GDSC1	0.3469	2.2695	0.1806	20.044
HEC-1-B	CTRP2	0.5708	3.737	0.5076	36.6659
HEC-50B	CTRP2	2.3994	12.2047	-0.4265	32.9207
HEC-1-A	CTRP2	2.5722	8.7209	1.2951	27.5679
EFE-184	CTRP2	3.5344	7.9778	2.6118	20.1148
Ishikawa (Heraklio) 02 ER-	CTRP2	-1.3318	-0.7207	-1.3318	49.1414

Cancer Drug Sensitivity Data Curated from 40 Cell Line(s) in Kidney Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
786-O	GDSC1; CTRP2	-4.8226	-1.3208	-4.8261	71.6484
KTCTL-195	GDSC1	-4.5535	0.3047	-4.7425	74.1363
KTCTL-140	GDSC1	-4.1989	1.6126	-4.614	69.2589
ACHN	GDSC1; CTRP2	-3.7866	-1.185	-3.7871	65.3985
BB65-RCC	GDSC1	-3.6099	2.8725	-4.31	55.3629
LB996-RCC	GDSC1	-3.289	3.2247	-4.0698	53.1756
769-P	GDSC1; CTRP2	-3.118	3.5633	-3.403	59.2493
SW13	GDSC1	-3.0445	-0.7124	-3.0579	52.1295
LB1047-RCC	GDSC1	-3.0278	2.196	-3.4825	51.5883
TK-10	GDSC1	-2.9873	2.152	-3.4267	51.2866
BFTC-909	GDSC1; CTRP2	-2.5632	0.8202	-2.5747	57.2242
A-498	GDSC1	-2.5609	2.5203	-3.0624	47.9589
RXF 393L	GDSC1	-2.4332	2.5439	-2.9298	46.9311
LB2241-RCC	GDSC1	-2.1474	0.1252	-2.1745	43.5401
KTCTL-21	GDSC1	-2.0878	2.2375	-2.4677	53.9286
HA7-RCC	GDSC1	-1.8163	3.2647	-2.4829	42.1765
CAL-54	GDSC1; CTRP2	-1.7377	1.9262	-1.7688	51.8051
SN12C	GDSC1	-1.6644	2.2279	-2.0032	39.9894
UO-31	GDSC1; CTRP2	-1.0842	3.6063	-1.2304	47.6371
SW156	GDSC1	-0.9208	3.5086	-1.5996	34.5099
KTCTL-1M	GDSC1	-0.687	3.1811	-1.2309	40.0171
KMRC-1	GDSC1; CTRP2	-0.5128	1.8645	-0.5179	43.699
Caki-1	GDSC1; CTRP2	-0.4295	18.2932	-6.0568	47.1589
KMRC-3	CTRP2	-0.3366	2.729	-0.3651	42.5876
NCC021	GDSC1	-0.2231	5.762	-1.8024	38.7837
KTCTL-13	GDSC1	-0.0815	4.4656	-1.0877	35.4133
TUHR4TKB	CTRP2	0.0069	2.6671	-0.0095	40.2728
NCC010	GDSC1	0.0326	4.6825	-1.0628	34.6157
TUHR10TKB	CTRP2	0.6298	2.7961	0.6218	36.0991
A-704	GDSC1	0.7446	4.559	-0.2817	20.9356
KTCTL-26A	GDSC1	0.9087	4.9682	-0.3068	25.8454
OS-RC-2	GDSC1; CTRP2	0.9442	11.3534	-1.5178	39.559
KMRC-20	GDSC1; CTRP2	1.188	5.8505	0.7962	33.6018
KMRC-2	CTRP2	1.3047	7.3637	0.4597	34.1682
SNU-1272	CTRP2	2.1949	3.5143	2.1929	25.6526
VMRC-RCW	GDSC1; CTRP2	2.4687	4.9462	2.3778	24.1303
Caki-2	CTRP2	2.4928	5.9542	2.1927	24.7013
TUHR14TKB	CTRP2	3.018	10.2543	1.0861	26.9588
VMRC-RCZ	GDSC1; CTRP2	3.1455	18.1316	-2.5575	35.0614
RCC10RGB	GDSC1; CTRP2	4.301	9.7938	2.5735	18.2618

Cancer Drug Sensitivity Data Curated from 59 Cell Line(s) in Large Intestine Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
CL-34	CTRP2	-7.1003	-1.5386	-7.1282	81.0705
HCC2998	GDSC1	-5.3151	-0.4628	-5.45	69.2497
SW48	GDSC1; CTRP2	-5.3083	-1.7214	-5.3115	74.5442
SW620	GDSC1; CTRP2	-4.7475	2.4258	-4.9786	67.4018
RKO	GDSC1; CTRP2	-4.0331	-0.4081	-4.0404	66.6229
GP5d	GDSC1	-3.8184	2.3734	-4.3933	56.9625
LS180	GDSC1; CTRP2	-3.6808	1.4642	-3.7533	63.4811
SK-CO-1	GDSC1; CTRP2	-3.1014	-0.1897	-3.1041	60.8347
LoVo	GDSC1; CTRP2	-2.9719	1.7068	-3.0327	59.4464
SW626	GDSC1	-2.7073	1.8552	-3.0466	49.0583
SNU-81	GDSC1; CTRP2	-2.6659	-1.0825	-2.6659	58.0287
NCI-H747	GDSC1; CTRP2	-2.0278	3.3117	-2.1972	53.4463
HCT 116	GDSC1; CTRP2	-1.9522	11.3027	-4.5227	51.8085
MDST8	GDSC1; CTRP2	-1.9457	0.2977	-1.9466	53.2272
LS123	GDSC1; CTRP2	-1.9431	4.9383	-2.3974	52.676
SNU-175	CTRP2	-1.9392	1.3237	-1.9528	53.1464
SNU-C5	GDSC1; CTRP2	-1.711	2.8139	-1.8042	51.5822
SNU-407	GDSC1; CTRP2	-1.5689	2.9658	-1.6696	50.6841
SW837	GDSC1	-1.4768	3.3999	-2.1612	39.3775
LS513	GDSC1; CTRP2	-1.457	2.6811	-1.5259	49.9764
HT115	GDSC1; CTRP2	-1.2854	1.4659	-1.2925	48.8378
OUMS-23	CTRP2	-1.2805	-0.623	-1.2805	48.7998
SNU-C2B	GDSC1	-1.1784	3.7569	-1.9675	37.1561
KM12	GDSC1; CTRP2	-0.914	1.5037	-0.9179	46.366
GP2d	CTRP2	-0.8941	4.2965	-1.1322	46.5301
NCI-H508	GDSC1; CTRP2	-0.6815	3.8628	-0.8357	45.0834
CL-11	GDSC1; CTRP2	-0.5479	6.5731	-1.301	45.0222
COLO 320HSR	GDSC1	-0.4769	3.3385	-1.06	30.0516
COLO 678	GDSC1; CTRP2	-0.2361	7.8658	-1.3812	43.7504
CCK-81	GDSC1; CTRP2	-0.2094	3.0535	-0.2528	41.7822
T84	GDSC1; CTRP2	-0.209	4.7766	-0.4805	42.277
COLO205	GDSC1; CTRP2	-0.1177	5.259	-0.4834	41.8839
COLO201	CTRP2	-0.0911	2.443	-0.1023	40.9092
SNU-C1	GDSC1; CTRP2	-0.0479	4.1647	-0.2015	40.9883
CaR-1	GDSC1	-0.0247	1.978	-0.1539	23.4588
HT-55	GDSC1; CTRP2	0.1259	4.1534	-0.0138	39.819
SNU-1040	GDSC1	0.2063	2.9665	-0.1903	28.9741
SNU-C2A	CTRP2	0.2098	5.4069	-0.1609	39.8318
SNU-1033	CTRP2	0.7107	4.3976	0.5764	35.9551
HCT 15	GDSC1; CTRP2	0.7669	3.8958	0.6986	35.3797
DiFi	GDSC1	0.7952	5.8111	-0.8151	29.2604
LS1034	GDSC1; CTRP2	0.915	6.9157	0.1864	36.2793
SW948	GDSC1; CTRP2	1.0562	5.8686	0.6476	34.507
LS411N	GDSC1; CTRP2	1.2096	11.2915	-1.2179	38.1943
SNU-61	GDSC1; CTRP2	1.3538	5.6566	1.0259	32.3203
SNU-503	CTRP2	1.4216	4.7391	1.2865	31.2475
CW-2	GDSC1; CTRP2	1.5046	4.0611	1.4586	30.3986
SW1463	GDSC1	1.676	5.3955	0.2185	14.7871
C2BBe1	GDSC1; CTRP2	1.7414	8.3319	0.5727	32.3821
NCI-H716	GDSC1; CTRP2	1.9191	4.6151	1.7406	22.9663
RCM-1 [Human ESC]	GDSC1; CTRP2	1.9254	7.4032	1.1166	30.1439
SNU-C4	CTRP2	1.9424	3.1921	1.9415	27.3311
SW1417	GDSC1; CTRP2	2.0446	7.7756	1.1088	29.7891
COLO 320	CTRP2	2.585	4.9676	2.4992	23.3382
SW1116	GDSC1; CTRP2	2.5861	12.0184	-0.1549	31.7269
HCT 8	CTRP2	2.7842	3.5281	2.7841	21.7204
DLD-1	CTRP2	3.1075	9.8211	1.3717	25.7708
HCC-56	CTRP2	3.3313	5.6251	3.1866	18.5739
HT-29	GDSC1; CTRP2	6.0496	19.6386	-0.7484	25.0586

Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Leukemia Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
MO-T	GDSC1	-1.3891	1.3048	-1.5026	36.5811

Cancer Drug Sensitivity Data Curated from 26 Cell Line(s) in Liver Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
HLE	GDSC1	-4.7231	-1.2076	-4.7618	66.7442
SK-HEP-1	GDSC1; CTRP2	-4.236	-1.4151	-4.2369	68.2804
JHH-7	GDSC1	-3.8513	1.5672	-4.225	57.7506
SNU-182	CTRP2	-2.8236	-1.2702	-2.8236	59.0793
HuH-6	CTRP2	-2.7449	0.4493	-2.7517	58.445
SNU-398	GDSC1; CTRP2	-2.4263	1.5669	-2.4603	56.2199
Huh-7	GDSC1	-2.1144	1.5143	-2.3254	43.7233
JHH-6	GDSC1; CTRP2	-2.0729	1.5424	-2.0964	53.9924
SNU-423	GDSC1; CTRP2	-2.0261	2.3292	-2.0926	53.5978
SNU-387	GDSC1; CTRP2	-1.9286	3.2047	-2.0778	52.8748
HLF	CTRP2	-1.9276	1.427	-1.944	53.0649
JHH-1	GDSC1; CTRP2	-1.8911	1.5794	-1.9117	52.8177
Hep-G2/C3A	GDSC1	-1.3755	1.9102	-1.6087	36.9416
PLC/PRF/5	CTRP2	-1.334	2.2643	-1.3698	49.173
Hep-G2	CTRP2	-1.3009	4.2644	-1.5654	49.0401
JHH-5	CTRP2	-1.2531	3.6132	-1.4115	48.7072
SNU-878	CTRP2	-0.5881	3.1825	-0.6586	44.3374
SNU-761	CTRP2	-0.4797	11.1523	-2.912	46.0208
JHH-4	GDSC1; CTRP2	-0.4625	2.8983	-0.5053	43.4543
Li-7	CTRP2	-0.2219	6.1926	-0.8353	42.9479
Hep 3B2.1-7	GDSC1; CTRP2	-0.1895	9.3502	-1.8794	44.1064
JHH-2	GDSC1; CTRP2	0.2049	4.3055	0.0483	39.3453
SNU-475	GDSC1; CTRP2	0.7668	3.8645	0.7016	35.3702
HuH-1	GDSC1; CTRP2	0.8637	5.412	0.5498	35.4809
SNU-886	CTRP2	1.4587	3.7269	1.4347	64.421
SNU-449	GDSC1; CTRP2	4.529	10.6595	2.3779	18.4623

Cancer Drug Sensitivity Data Curated from 217 Cell Line(s) in Lung Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
LC-2/ad	GDSC1	-6.8388	-2.7577	-6.8654	81.3195
DV-90	CTRP2	-5.9756	1.7462	-6.1982	72.5064
A-427	GDSC1	-5.8075	-1.3338	-5.8813	73.4953
SBC-3	GDSC1	-5.7662	-2.6009	-5.7767	75.9179
NCI-H2110	GDSC1; CTRP2	-5.3796	-2.9775	-5.3797	75.8397
Lu-135	GDSC1	-5.1957	-2.8839	-5.1974	72.3722
LCLC-97TM1	GDSC1; CTRP2	-5.0941	0.0282	-5.1331	71.635
EMC-BAC-2	GDSC1	-5.0786	1.1851	-5.4749	73.9199
NCI-H1651	GDSC1	-4.7614	0.3556	-4.9738	64.8101
NCI-H1781	GDSC1	-4.6645	-2.6228	-4.6655	67.6601
NCI-H460	GDSC1; CTRP2	-4.6118	-1.8622	-4.6123	70.7419
NCI-H1184	CTRP2	-4.5133	-0.3376	-4.528	69.2247
NCI-H3122	GDSC1	-4.4174	-1.7907	-4.4259	64.9673
COR-L23	GDSC1	-4.3482	-1.8877	-4.354	64.442
NCI-H1734	GDSC1; CTRP2	-4.3202	-1.6277	-4.3207	68.8699
HCC44	GDSC1; CTRP2	-4.2892	-2.2682	-4.2892	68.8063
NCI-H292	GDSC1; CTRP2	-4.1392	-1.1501	-4.1407	67.5922
HOP-62	GDSC1; CTRP2	-4.0954	-0.3487	-4.1043	66.9474
NCI-H2122	GDSC1; CTRP2	-4.0772	-0.4142	-4.0848	66.8804
NCI-H209	GDSC1; CTRP2	-4.0704	-0.2852	-4.0801	66.7679
SBC-5	GDSC1; CTRP2	-4.0566	-1.411	-4.0571	67.1612
NCI-H2087	GDSC1; CTRP2	-3.9694	0.1391	-3.987	65.9397
NCI-H2228	GDSC1; CTRP2	-3.9329	6.9311	-5.0986	60.4202
NCI-H526	GDSC1; CTRP2	-3.9265	-1.7251	-3.9266	66.3844
NCI-H211	GDSC1; CTRP2	-3.9057	-1.086	-3.9068	66.1286
HCC78	GDSC1; CTRP2	-3.8848	0.9596	-3.9331	64.9143
NCI-H1975	GDSC1; CTRP2	-3.8384	-0.533	-3.8426	65.5285
NCI-H2369	GDSC1	-3.7557	0.426	-3.9058	57.8985
SK-MES-1	GDSC1; CTRP2	-3.7173	0.4833	-3.7403	64.3179
NCI-H2030	GDSC1; CTRP2	-3.7123	2.4501	-3.8802	62.8977
Lu-99A	GDSC1	-3.6774	-0.2295	-3.7445	57.684
NCI-H1437	GDSC1	-3.6264	0.2165	-3.7393	57.0119
IST-SL2	GDSC1	-3.6257	0.3926	-3.762	56.9038
NCI-H358	GDSC1; CTRP2	-3.6041	0.5303	-3.6263	63.6487
NCI-H1048	GDSC1	-3.5443	-1.0227	-3.558	56.8544
NCI-H2804	GDSC1	-3.5426	1.0916	-3.7891	55.8636
CPC-N	GDSC1	-3.4974	2.3227	-4.0291	54.907
Lu-99	CTRP2	-3.4666	-0.0849	-3.473	63.1012
ABC-1	GDSC1	-3.4609	-0.583	-3.4922	55.962
SW1271	GDSC1; CTRP2	-3.375	3.991	-3.7563	60.1992
Calu-3	GDSC1; CTRP2	-3.3544	5.7638	-4.1376	58.9873
NCI-H661	GDSC1; CTRP2	-3.3259	1.3493	-3.3773	61.6315
EMC-BAC-1	GDSC1	-3.3111	-0.161	-3.3664	67.6166
NCI-H810	GDSC1; CTRP2	-3.2966	0.3934	-3.3095	61.898
NCI-H1694	GDSC1; CTRP2	-3.2877	-0.846	-3.2882	62.1289
NCI-H290	GDSC1	-3.2349	-0.004	-3.3006	53.7759
NCI-H2009	GDSC1; CTRP2	-3.2303	0.1069	-3.237	61.5825
NCI-H23	GDSC1; CTRP2	-3.2225	0.0272	-3.2281	61.5554
COR-L279	GDSC1; CTRP2	-3.2089	-0.4542	-3.2105	77.5463
NCI-H1568	GDSC1; CTRP2	-3.1687	0.0637	-3.1743	61.2087
NCI-H1666	GDSC1; CTRP2	-3.1469	1.4858	-3.2001	60.5499
SBC-1	GDSC1	-3.1362	1.2917	-3.3883	52.6119
NCI-H2722	GDSC1	-3.1214	1.1371	-3.342	52.5266
Lu-134-A	GDSC1	-3.0965	1.866	-3.4734	52.1716
NCI-H64	GDSC1	-3.0698	-0.5543	-3.2127	39.5236
NCI-H1876	GDSC1	-3.0661	-0.2349	-3.1049	52.2868
NCI-H1650	GDSC1; CTRP2	-2.9984	1.6536	-3.0568	59.6224
RERF-LC-KJ	GDSC1	-2.9721	0.8022	-3.1229	51.3205
COLO 668	GDSC1; CTRP2	-2.9557	-1.2805	-2.9557	59.9583
NCI-H3255	GDSC1	-2.9528	0.522	-3.0616	51.1771
EBC-1	GDSC1; CTRP2	-2.9064	1.0308	-2.9305	59.3131
NCI-H2347	GDSC1	-2.8177	0.8098	-2.9584	49.9625
NCI-H596	GDSC1	-2.7771	2.5607	-3.3098	49.6581
NCI-H1703	GDSC1; CTRP2	-2.7601	0.1929	-2.7639	58.5814
CAL-12T	GDSC1; CTRP2	-2.6982	4.9773	-3.2279	56.4962
NCI-H2171	GDSC1; CTRP2	-2.6431	0.4566	-2.6491	57.7915
NCI-H2595	GDSC1	-2.5491	2.9223	-3.1693	47.9452
RERF-LC-A1	CTRP2	-2.4844	0.8371	-2.4951	56.7183
NCI-H748	GDSC1	-2.4838	0.4049	-2.8233	33.4815
HARA [Human squamous cell lung carcinoma]	GDSC1; CTRP2	-2.4792	0.8409	-2.4899	56.6843
NCI-H1770	GDSC1	-2.443	0.8299	-2.5599	46.5449
SK-LU-1	GDSC1; CTRP2	-2.4082	6.0163	-3.1725	54.7397
LC-1/sq	GDSC1	-2.3718	1.4888	-2.5995	46.0738
ChaGo-K-1	GDSC1; CTRP2	-2.3186	1.6824	-2.3551	55.5265
DMS 273	GDSC1; CTRP2	-2.2994	1.9418	-2.35	55.3567
NCI-H2591	GDSC1	-2.2627	1.4546	-2.4741	45.068
NCI-H441	GDSC1; CTRP2	-2.2409	5.6128	-2.8835	54.0573
NCI-H1944	GDSC1; CTRP2	-2.2366	2.49	-2.3263	54.8566
NCI-H2810	GDSC1	-2.1779	2.3621	-2.5999	54.662
LXF 289	GDSC1; CTRP2	-2.1225	1.8618	-2.1622	54.2675
NCI-H146	GDSC1; CTRP2	-2.1183	4.6376	-2.5229	53.675
NCI-H2135	GDSC1	-2.1043	0.5164	-2.1613	43.2202
LCLC-103H	GDSC1; CTRP2	-2.0733	2.7255	-2.177	53.8237
LB647-SCLC	GDSC1	-2.0283	4.6373	-3.2108	44.6935
NCI-H510A	GDSC1	-2.0278	2.073	-2.9765	31.5008
NCI-H2196	GDSC1; CTRP2	-2.0085	-0.0493	-2.0088	53.6481
NCI-H1341	GDSC1; CTRP2	-1.9867	-0.5196	-1.9867	53.5041
NCI-H838	GDSC1; CTRP2	-1.97	0.4167	-1.9713	53.3859
NCI-H513	GDSC1	-1.9423	3.8068	-2.8077	43.5765
EPLC-272H	GDSC1; CTRP2	-1.9417	1.5604	-1.9628	53.1464
NCI-H1304	GDSC1	-1.9167	0.8345	-1.9988	41.5099
NCI-H2461	GDSC1	-1.8583	1.9757	-2.1504	41.6073
PC-14	GDSC1; CTRP2	-1.8559	2.0208	-1.8956	52.5587
NCI-H2286	CTRP2	-1.8359	3.4127	-2.0061	52.2919
NCI-H1648	GDSC1	-1.8359	5.9584	-3.546	44.0812
NCI-H2373	GDSC1	-1.8273	0.4413	-1.8637	40.4841
NCI-H522	GDSC1; CTRP2	-1.8098	2.0459	-1.8493	52.2616
NCI-H2081	GDSC1; CTRP2	-1.7798	4.634	-2.1548	51.8236
NCI-H847	GDSC1	-1.7438	0.6805	-1.7978	39.7476
Ms-1	GDSC1	-1.7172	1.7018	-1.9335	40.0793
HCC1588	CTRP2	-1.7057	3.4575	-1.8733	51.5037
NCI-H1105	GDSC1; CTRP2	-1.6485	3.0025	-1.7575	51.1812
NCI-H226	GDSC1; CTRP2	-1.5553	6.9098	-2.5009	50.4729
DMS 114	GDSC1; CTRP2	-1.5478	1.0024	-1.5511	50.5783
A-549	GDSC1; CTRP2	-1.545	5.7735	-2.1657	50.4546
NCI-H2085	GDSC1	-1.4892	4.5566	-2.606	40.5925
NCI-H1581	GDSC1; CTRP2	-1.4747	0.1021	-1.4747	50.0931
NCI-H2869	GDSC1	-1.4747	3.0908	-2.0543	39.0482
NCI-H1838	GDSC1; CTRP2	-1.4689	2.8992	-1.5577	50.0525
NCI-H2023	GDSC1; CTRP2	-1.4619	4.7728	-1.8386	50.0069
NCI-H647	GDSC1; CTRP2	-1.4501	5.4274	-1.9747	49.941
NCI-H2405	GDSC1; CTRP2	-1.3931	4.2379	-1.6601	49.5955
NCI-H650	GDSC1; CTRP2	-1.3908	2.1747	-1.4237	49.5434
HCC1438	CTRP2	-1.3688	0.2047	-1.3688	49.3876
NCI-H841	GDSC1; CTRP2	-1.3191	3.4632	-1.462	49.1147
HCC366	GDSC1; CTRP2	-1.2509	2.9403	-1.3324	48.6558
LK-2	GDSC1	-1.2431	0.5354	-1.2627	34.7474
Lu-139	GDSC1	-1.2336	1.6613	-1.4	35.3181
NCI-H187	GDSC1	-1.2311	0.4721	-1.2468	34.6118
UMC-11	GDSC1	-1.2191	0.7039	-1.2491	34.5633
NCI-H2170	GDSC1; CTRP2	-1.2071	3.3305	-1.3268	48.3974
LK2	CTRP2	-1.2049	1.6439	-1.2145	48.3063
COR-L95	GDSC1; CTRP2	-1.1883	6.459	-1.9659	48.562
NCI-H1688	GDSC1	-1.1843	1.2944	-1.2809	34.5345
RERF-LC-MS	GDSC1; CTRP2	-1.1796	2.1554	-1.2054	48.1538
NCI-H2795	GDSC1	-1.1606	1.6401	-1.3166	34.5735
NCI-H2126	CTRP2	-1.1548	3.1718	-1.254	48.0508
NCI-H1963	GDSC1	-1.1292	1.8232	-1.9496	20.3371
NCI-H1155	GDSC1; CTRP2	-1.1252	1.1133	-1.127	47.7681
NCI-H2106	CTRP2	-1.1234	3.55	-1.2649	47.8816
NCI-H2029	GDSC1; CTRP2	-1.1175	2.3538	-1.1511	47.7532
MOR/CPR	CTRP2	-1.0963	0.4845	-1.0963	47.5723
NCI-H1623	GDSC1; CTRP2	-1.0933	2.6085	-1.1793	44.0078
PaCa-3	GDSC1	-0.9816	1.8525	-1.1668	32.9884
DMS 454	CTRP2	-0.9773	6.8296	-1.8466	47.476
DMS 53	GDSC1; CTRP2	-0.9642	1.9664	-0.978	46.7164
HCC15	GDSC1; CTRP2	-0.8135	5.2841	-1.2467	46.2331
HCC827	GDSC1; CTRP2	-0.7998	2.1013	-0.8145	45.628
IST-SL1	GDSC1	-0.7531	2.9657	-1.2294	32.1373
NCI-H69	GDSC1; CTRP2	-0.735	4.9981	-1.097	45.6867
Lu-65	GDSC1; CTRP2	-0.73	3.2257	-0.8118	45.2846
NCI-H1563	GDSC1; CTRP2	-0.7171	2.5883	-0.7504	45.116
HOP-92	GDSC1; CTRP2	-0.6997	4.2122	-0.9086	45.2777
NCI-H1339	CTRP2	-0.694	3.9782	-0.8657	45.1887
NCI-H446	GDSC1; CTRP2	-0.678	3.3547	-0.7699	44.9625
NCI-H2342	GDSC1; CTRP2	-0.6654	8.9321	-2.229	46.3185
NCI-H2818	GDSC1	-0.6542	1.7271	-0.7851	29.5719
HCC2279	CTRP2	-0.5801	2.9707	-0.6328	44.2503
NCI-H1355	GDSC1; CTRP2	-0.5598	7.7977	-1.7079	45.4721
COR-L105	GDSC1; CTRP2	-0.5306	8.357	-1.8731	45.4887
Calu-6	GDSC1; CTRP2	-0.5153	3.396	-0.6025	43.8931
NCI-H1435	GDSC1; CTRP2	-0.5122	4.4271	-0.7432	44.1256
NCI-H1993	GDSC1	-0.4434	1.4757	-0.5141	27.2291
NCI-H1395	CTRP2	-0.4242	3.2584	-0.4934	43.2592
NCI-H2803	GDSC1	-0.3513	5.3362	-1.7431	32.3533
NCI-H1792	GDSC1; CTRP2	-0.2655	4.9332	-0.5733	42.7021
HCC2108	CTRP2	-0.2558	2.1058	-0.2619	41.9908
NCI-H82	GDSC1	-0.2369	2.4721	-0.513	26.2671
NCI-H1693	GDSC1; CTRP2	-0.2144	6.9877	-1.0651	43.2516
COR-L32	GDSC1	-0.2047	6.887	-2.3004	39.9752
NCI-H520	GDSC1; CTRP2	-0.1697	3.1561	-0.2188	41.5342
DMS 79	GDSC1; CTRP2	-0.1656	4.9097	-0.46	42.0467
NCI-H2141	GDSC1; CTRP2	-0.1613	4.31	-0.3455	41.7929
NCI-H889	CTRP2	-0.1456	3.3393	-0.2084	41.4094
NCI-H1092	GDSC1; CTRP2	-0.1013	4.4791	-0.3092	41.4569
NCI-H2731	GDSC1	-0.0655	1.839	-0.1694	23.726
HCC1833	CTRP2	-0.0554	4.4321	-0.2517	41.1351
VMRC-LCD	GDSC1; CTRP2	-0.0492	5.0866	-0.3709	41.3653
Lu-165	GDSC1	-0.0443	5.0823	-1.317	29.2709
COLO 699	CTRP2	-0.0025	2.5761	-0.016	40.3267
NCI-H1385	CTRP2	0.0568	8.5789	-1.3228	42.4845
NCI-H1915	GDSC1; CTRP2	0.1103	2.7349	0.0938	39.5849
Sq-1	CTRP2	0.1221	1.444	0.1221	39.4551
RERF-LC-Sq1	GDSC1	0.1323	2.5475	-0.1329	22.644
NCI-H1793	GDSC1; CTRP2	0.1338	6.2835	-0.4729	40.799
NCI-H1869	GDSC1; CTRP2	0.2424	3.2115	0.206	38.7659
NCI-H196	GDSC1; CTRP2	0.2574	4.661	0.0457	39.1444
NCI-H1836	GDSC1	0.3531	5.2774	-1.0023	26.1806
LOU-NH91	GDSC1; CTRP2	0.3669	3.5604	0.3096	38.0014
HCC95	CTRP2	0.3965	4.8059	0.1692	38.2803
NCI-H1755	GDSC1; CTRP2	0.401	4.6967	0.1943	38.1963
NCI-H524	GDSC1	0.4779	1.6382	0.4467	18.078
NCI-H1436	GDSC1	0.5069	2.808	0.19	19.2959
NCI-H1299	GDSC1; CTRP2	0.5351	4.3803	0.3909	37.143
HCC33	GDSC1	0.571	3.8734	-1.4584	9.9012
KNS-62	GDSC1; CTRP2	0.6687	2.9989	0.6554	35.8572
NCI-H2172	GDSC1; CTRP2	0.7735	6.0152	0.3	36.5049
NCI-H2444	GDSC1; CTRP2	0.8045	7.1673	-0.0159	37.1849
LUDLU-1	CTRP2	0.8748	5.7229	0.4871	35.6195
NCI-H322	CTRP2	0.97	4.7396	0.8004	34.3504
EKVX	GDSC1; CTRP2	1.1076	6.0696	0.6499	34.3186
NCI-H2227	GDSC1	1.1346	5.7778	-0.4734	20.5333
NCI-H727	GDSC1; CTRP2	1.2294	9.4391	-0.4112	36.5633
NCI-H1573	GDSC1; CTRP2	1.3353	3.6758	1.31	31.4571
NCI-H1373	CTRP2	1.4345	6.6886	0.8238	32.6711
NCI-H835	GDSC1	1.4367	6.6996	-0.6423	25.2965
HCC4006	CTRP2	1.5407	2.8864	1.5399	30.0072
SHP-77	GDSC1; CTRP2	1.6133	3.5432	1.6021	29.5579
HCC2935	CTRP2	1.7128	9.458	0.0887	33.7766
NCI-H2291	GDSC1; CTRP2	1.7729	9.1091	0.2958	33.0428
COR-L88	GDSC1; CTRP2	1.8729	7.0239	1.1912	30.0738
NCI-H2066	GDSC1	1.9171	5.1513	0.5572	15.3516
NCI-H345	GDSC1	2.1647	7.7514	-0.5249	17.4517
LC-1/sq-SF	CTRP2	2.2451	6.782	1.6755	27.2791
NCI-H720	GDSC1	2.331	4.9468	1.017	7.9752
COR-L321	GDSC1	2.3397	7.5542	-0.2794	19.4565
RERF-LC-Ad2	CTRP2	2.3972	8.3176	1.275	28.16
HCC1195	CTRP2	2.4911	9.0326	1.0801	28.506
NCI-H322M	GDSC1	2.6897	5.8611	0.8487	8.0423
SW1573	GDSC1; CTRP2	2.7084	12.2945	-0.1625	31.3985
T3M-10	CTRP2	2.8255	7.9614	1.8706	24.8483
BEN	GDSC1; CTRP2	3.0113	9.6265	1.3605	26.0782
RERF-LC-Ad1	CTRP2	4.305	11.5617	1.7294	21.4076
IA-LM	GDSC1; CTRP2	5.5795	17.2028	0.0732	23.826
Calu-1	CTRP2	5.597	14.0975	1.6392	18.8079
HCC1171	CTRP2	6.9157	17.0508	1.2493	17.5683
Hs 888.Lu	CTRP2	1.446	12.3476	-1.4472	37.8344

Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Lymphoma Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
CBTCi002-A	GDSC1	-0.4178	1.8092	-0.5453	27.2643

Cancer Drug Sensitivity Data Curated from 3 Cell Line(s) in Thigh Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
SYO-1	CTRP2	-5.5716	2.5649	-5.88	70.1372
H-STS	CTRP2	-3.6407	-0.9768	-3.6426	61.8915
P-STS	CTRP2	-3.1709	1.6067	-3.2328	60.6267

Cancer Drug Sensitivity Data Curated from 45 Cell Line(s) in Ovary Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
2004	CTRP2	-5.4593	0.7075	-5.551	72.2338
A2780	GDSC1; CTRP2	-5.8305	-0.8253	-5.8552	75.778
OC 314	GDSC1; CTRP2	-5.0458	-3.7314	-5.0458	73.8791
OVK18	GDSC1; CTRP2	-4.2691	-0.5577	-4.2766	68.0582
COV434	CTRP2	-3.864	-0.5446	-3.8683	65.6875
TOV-112D	GDSC1; CTRP2	-3.547	-0.6657	-3.5487	63.7658
OVCAR-8	GDSC1; CTRP2	-3.5344	-0.405	-3.5378	63.6198
JHOS-2	GDSC1	-2.757	3.3312	-3.526	58.2701
OVCAR-5	GDSC1; CTRP2	-2.6318	2.3896	-2.7321	57.2159
IGROV-1	GDSC1; CTRP2	-2.6141	3.6066	-2.8683	56.6483
DOV13	GDSC1; CTRP2	-2.4698	2.6393	-2.5863	56.1956
OVCAR-3	GDSC1	-2.461	3.79	-3.3614	47.4816
SK-OV-3	GDSC1; CTRP2	-2.2386	4.2621	-2.5783	54.4159
Caov-4	GDSC1	-2.059	2.3939	-2.479	43.6905
OVCAR-4	GDSC1; CTRP2	-1.9262	2.2195	-1.9806	52.9862
JHOC-5	CTRP2	-1.6711	0.609	-1.6723	51.3995
TYK-nu	GDSC1; CTRP2	-1.6442	3.403	-1.8005	51.1329
Caov-3	GDSC1; CTRP2	-1.5398	3.0603	-1.6488	50.4985
HEY A8	CTRP2	-1.4321	3.4862	-1.5853	49.8222
SNU-119	CTRP2	-1.4235	0.4974	-1.4238	49.7523
JHOS-4	GDSC1	-1.3465	3.1982	-1.951	46.9057
MCAS	CTRP2	-1.3344	5.595	-1.8902	49.3014
RMG-I	GDSC1; CTRP2	-1.2541	2.0567	-1.2776	48.6423
Kuramochi	GDSC1; CTRP2	-1.0746	5.0853	-1.4854	47.7594
ES-2	GDSC1	-0.9847	1.0785	-1.0386	32.4017
TOV-21G	GDSC1; CTRP2	-0.8264	2.7736	-0.8751	45.8618
OVISE	GDSC1; CTRP2	-0.784	6.483	-1.5319	46.3411
OV7	CTRP2	-0.5286	8.4483	-1.904	45.5061
OAW42	GDSC1; CTRP2	-0.4673	4.2128	-0.6588	43.7741
OVSAHO	CTRP2	-0.3957	3.5102	-0.4882	43.1222
COV644	CTRP2	-0.3481	1.982	-0.3532	42.6023
SNU-8	CTRP2	-0.339	1.673	-0.3407	42.5324
OAW28	GDSC1; CTRP2	-0.27	5.2325	-0.6432	42.8467
FU-OV-1	GDSC1; CTRP2	0.1511	9.7899	-1.6912	42.5922
ONCO-DG-1	CTRP2	0.1894	5.4368	-0.1903	39.9812
ES2	CTRP2	0.5152	6.4136	-0.0945	38.4668
COV362	CTRP2	0.9023	9.1742	-0.6499	38.1968
OV56	GDSC1; CTRP2	0.9584	3.4544	0.9329	33.9677
SNU-840	CTRP2	1.2616	5.7543	0.9011	33.026
JHOM-1	CTRP2	1.9272	4.2719	1.8831	27.5777
OV-90	GDSC1; CTRP2	2.0864	8.8053	0.7499	30.7616
EFO-21	GDSC1; CTRP2	2.1245	9.8818	0.3375	31.8175
EFO-27	GDSC1; CTRP2	2.1448	11.179	-0.2138	33.17
OVKATE	GDSC1	3.2216	12.7184	-2.1469	21.9318
OVTOKO	GDSC1; CTRP2	3.2853	11.2409	0.8981	26.8164

Cancer Drug Sensitivity Data Curated from 31 Cell Line(s) in Soft Tissue Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
Yamato-SS	CTRP2	-1.8018	2.7206	-1.8909	52.1566
Aska-SS	CTRP2	-1.5842	1.4998	-1.5964	50.8151
MFH-ino	GDSC1	-7.4477	-3.8302	-7.4564	86.2341
EW-8	GDSC1	-6.3602	-5.2871	-6.3602	84.2189
A-204	GDSC1; CTRP2	-5.8848	-1.4272	-5.8961	76.835
SW982	GDSC1; CTRP2	-5.7915	0.2213	-5.863	74.1205
TE 617.T	CTRP2	-5.6039	-2.6867	-5.6043	76.9276
Hs 633.T	GDSC1	-5.5426	-1.9573	-5.5687	73.3353
HT-1080	GDSC1; CTRP2	-5.3902	-1.9565	-5.3922	75.1795
TE 441.T	GDSC1; CTRP2	-5.2723	-1.8592	-5.2745	74.4827
G-401	GDSC1; CTRP2	-5.0327	-0.2322	-5.0599	71.6619
STS-0421	GDSC1	-4.7861	0.4449	-5.0152	64.8291
SK-UT-1	GDSC1; CTRP2	-4.7612	-1.5959	-4.7628	71.4889
VA-ES-BJ	GDSC1	-4.5442	-0.1023	-4.6752	64.0683
TTC-709	CTRP2	-4.2582	0.7855	-4.3092	66.9576
MES-SA	GDSC1	-3.8334	-0.4852	-3.8861	59.138
Tm87-16	CTRP2	-3.7515	0.7895	-3.7873	64.3189
G-402	GDSC1; CTRP2	-3.4434	0.4679	-3.4606	62.745
KYM-1	GDSC1; CTRP2	-3.1619	-1.3628	-3.162	61.3295
Rh30	GDSC1	-3.078	-0.1589	-3.1229	52.3872
Rh41	GDSC1; CTRP2	-2.8644	-1.4607	-2.8644	59.3511
SW872	GDSC1	-2.8481	-0.6506	-2.8594	50.2517
RD	GDSC1; CTRP2	-2.3692	2.1198	-2.4346	55.7436
BT-12	CTRP2	-2.3248	-1.5054	-2.3248	55.7566
Hs 729.T	CTRP2	-2.1187	2.7698	-2.2294	54.0893
BT-16	CTRP2	-1.8507	-0.59	-1.8507	52.5985
GCT	GDSC1; CTRP2	-1.3808	0.9251	-1.3826	49.4686
RKN	GDSC1; CTRP2	-1.1264	1.2814	-1.1296	47.778
Rh18	GDSC1; CTRP2	-0.4937	6.817	-1.3159	44.7928
SW684	GDSC1	0.2948	2.4664	0.0686	20.864
SK-LMS-1	GDSC1; CTRP2	1.9542	10.9077	-0.2864	33.9258

Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Clivus Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
U-CH1	CTRP2	4.0523	11.052	1.7343	22.0143

Cancer Drug Sensitivity Data Curated from 8 Cell Line(s) in Pleura Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
NCI-H28	GDSC1; CTRP2	-3.7002	-1.3992	-3.7004	64.8752
MSTO-211H	GDSC1; CTRP2	-3.2708	1.5699	-3.3341	61.2047
IST-Mes1	GDSC1; CTRP2	-1.7589	3.5186	-1.9385	51.8193
MPP 89	GDSC1; CTRP2	-1.7586	3.2741	-1.9057	51.8401
NCI-H2052	GDSC1; CTRP2	-0.5756	4.4445	-0.8147	44.5385
JL-1	CTRP2	-0.4087	2.3031	-0.4218	43.0271
NCI-H2452	GDSC1; CTRP2	-0.1855	3.7491	-0.2927	41.7784
ACC-MESO-1	CTRP2	0.2855	3.5143	0.2283	38.5411

Cancer Drug Sensitivity Data Curated from 7 Cell Line(s) in Prostate Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
22Rv1	GDSC1; CTRP2	-3.7848	-0.1693	-3.7931	65.0506
LNCaP clone FGC	GDSC1; CTRP2	-3.2192	0.6692	-3.238	61.3286
DU145	GDSC1; CTRP2	-3.0798	4.2376	-3.4843	58.677
VCaP	GDSC1; CTRP2	-2.126	0.7187	-2.1307	54.4042
PC-3	GDSC1	-0.3174	2.8808	-0.7284	27.7195
NCI-H660	CTRP2	-0.0132	3.7226	-0.107	40.6151
PaCa-3	CTRP2	4.3467	10.1376	2.4545	18.609

Cancer Drug Sensitivity Data Curated from 2 Cell Line(s) in Salivary Gland Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
A-253	GDSC1	-4.7422	-0.8711	-4.805	66.4251
YD-15	CTRP2	-3.1509	-1.0897	-3.151	61.2478

Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Small Intestine Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
HuTu 80	GDSC1	-7.3714	-5.1171	-7.3715	89.7864

Cancer Drug Sensitivity Data Curated from 44 Cell Line(s) in Stomach Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
HGC-27	GDSC1; CTRP2	-6.0091	-2.4838	-6.0108	78.7364
AGS	GDSC1; CTRP2	-4.7958	-1.7029	-4.7971	71.7506
RF-48	GDSC1	-4.7564	2.1121	-5.3466	62.5046
MKN1	GDSC1; CTRP2	-4.5494	-0.6748	-4.5581	69.6835
MKN28	GDSC1	-4.2999	-0.9329	-4.3401	63.2602
SNU-16	GDSC1; CTRP2	-4.1959	-1.0643	-4.198	67.9008
23132/87	GDSC1; CTRP2	-4.0956	-1.2808	-4.0965	67.3687
NUGC-3	GDSC1; CTRP2	-3.9558	-0.8055	-3.9585	66.3462
SNU-1	GDSC1; CTRP2	-3.6195	0.4992	-3.641	63.7531
SK-GT-2	GDSC1	-3.4483	-0.4793	-3.4856	69.3957
ECC10	GDSC1; CTRP2	-3.3875	-0.7348	-3.3885	62.7612
IM95	GDSC1; CTRP2	-3.2584	0.4664	-3.2724	61.6403
GSS	CTRP2	-3.2559	-0.2155	-3.2592	61.8233
RERF-GC-1B	GDSC1	-3.2336	-0.7315	-3.2508	53.9131
TMK-1	GDSC1	-2.8127	0.6571	-2.9305	49.9173
NUGC-4	GDSC1; CTRP2	-2.6561	0.9957	-2.6737	57.7767
Fu97	GDSC1; CTRP2	-2.6243	0.0602	-2.6263	57.7136
SNU-668	CTRP2	-2.2697	-0.2883	-2.2698	55.3864
OCUM-1	GDSC1; CTRP2	-2.1295	2.4652	-2.2117	54.2121
NCI-N87	GDSC1; CTRP2	-2.0486	2.975	-2.1776	53.6303
Hs 746.T	GDSC1; CTRP2	-1.9804	5.0223	-2.4569	52.86
SNU-5	GDSC1; CTRP2	-1.7536	0.5914	-1.7551	51.9481
SNU-620	CTRP2	-1.7398	-0.0661	-1.7399	51.8592
NCC-StC-K140	CTRP2	-1.6602	-0.2878	-1.6602	51.3294
ECC12	CTRP2	-1.5783	-0.3467	-1.5783	50.7833
SNU-601	CTRP2	-1.5118	1.5691	-1.5245	50.3369
GSU	CTRP2	-0.951	0.0835	-0.951	46.6041
SNU-719	CTRP2	-0.5496	2.9502	-0.5995	44.0438
GCIY	GDSC1	-0.5361	2.3165	-1.6112	15.1487
SCH	GDSC1	0.1638	0.9088	0.1626	20.9834
MKN7	GDSC1; CTRP2	0.1837	5.5915	-0.2338	40.1007
TGBC11TKB	GDSC1	0.2087	1.7054	0.1501	20.8323
HuG1-N	CTRP2	0.2227	3.9907	0.1114	39.1081
HSC-39	GDSC1	0.2257	1.2403	0.216	20.4232
SNU-216	CTRP2	0.5009	4.7025	0.3011	37.5246
MKN74	CTRP2	0.8131	6.1821	0.2971	36.3663
LMSU	CTRP2	1.5207	6.0179	1.1148	31.4753
SH-10-TC	CTRP2	1.5308	2.4301	1.5308	30.07
KATO III	GDSC1; CTRP2	4.5486	13.5978	0.9587	23.4387
KE-39	CTRP2	6.7463	15.7284	1.7742	16.0626
MKN45	GDSC1; CTRP2	9.1545	27.1782	-2.0558	22.8023
SNG-M	GDSC1; CTRP2	-4.3444	0.4828	-4.3829	67.6553
SNU-685	CTRP2	0.6651	3.8658	0.5943	36.0635
SNU-1077	CTRP2	3.3219	8.7738	2.053	22.7827

Cancer Drug Sensitivity Data Curated from 18 Cell Line(s) in Thyroid Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
IHH-4	GDSC1	-6.6515	-4.2609	-6.652	84.4624
8505C	GDSC1; CTRP2	-4.539	0.1613	-4.5691	68.9141
ASH-3	GDSC1	-4.3198	0.7926	-4.5734	61.5395
ML-1 [Human leukemia]	GDSC1; CTRP2	-4.2626	3.8623	-4.6921	64.0516
K5	GDSC1	-4.054	1.5333	-4.4379	59.1041
KMH-2	GDSC1	-4.0141	-1.497	-4.0231	61.2839
B-CPAP	GDSC1; CTRP2	-3.812	-0.6708	-3.8149	65.419
CAL-62	GDSC1; CTRP2	-3.7836	-1.1439	-3.7843	65.3716
CGTH-W-1	GDSC1; CTRP2	-3.2323	-0.5128	-3.2336	61.7272
SW579	CTRP2	-2.871	-0.0726	-2.8733	59.333
FTC-238	CTRP2	-2.4365	-0.3853	-2.4368	56.4963
BHT-101	GDSC1; CTRP2	-1.9995	1.479	-2.0191	53.5263
TT2609-C02	GDSC1; CTRP2	-1.7618	5.0866	-2.2336	51.6743
HTC-C3	GDSC1	-1.7363	2.6087	-2.1885	40.9642
FTC-133	GDSC1; CTRP2	-1.6952	0.5057	-1.6961	51.5604
8305C	GDSC1; CTRP2	-1.3461	1.6298	-1.3576	49.2425
WRO	GDSC1	-0.275	5.2987	-1.6485	31.6496
TT	GDSC1; CTRP2	0.0392	2.8057	0.0181	40.0715

Cancer Drug Sensitivity Data Curated from 56 Cell Line(s) in Upper Aerodigestive Tract Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
JHU-011	GDSC1	-6.3659	-4.8792	-6.3659	83.8576
JHU-029	GDSC1	-6.1006	-1.1864	-6.2018	74.5255
PCI-06A	GDSC1	-5.3877	-1.3567	-5.4418	71.2932
NCI-H3118	GDSC1	-5.3861	-1.5948	-5.4253	71.7228
PCI-04B	GDSC1	-5.3647	-2.9182	-5.3669	73.7281
BB30-HNC	GDSC1	-5.2711	-1.7004	-5.3012	71.1993
Ca9-22	GDSC1	-4.8822	-1.2564	-4.9236	67.9271
BB49-HNC	GDSC1	-4.7446	4.387	-6.0385	60.1586
OSC-20	GDSC1	-4.5923	-2.3121	-4.5949	66.8377
KOSC-2	GDSC1	-4.486	0.0743	-4.6366	63.4621
KON	GDSC1	-4.3829	-1.5346	-4.3976	64.4743
CAL-27	GDSC1; CTRP2	-4.2096	-0.7279	-4.2145	67.8179
HSC-2	GDSC1; CTRP2	-3.926	-1.3025	-3.9266	66.3104
BHY	GDSC1; CTRP2	-3.7396	-0.3524	-3.745	64.8601
HO-1-N-1	GDSC1	-3.619	0.2721	-3.7385	56.9199
HSC-4	GDSC1; CTRP2	-3.5454	-0.1175	-3.552	63.5935
HSC-3	GDSC1; CTRP2	-3.49	-0.8958	-3.4907	63.4462
SAS	GDSC1	-3.4185	-0.8529	-3.4355	55.6532
HO-1-u-1	GDSC1	-3.293	0.4433	-3.4138	54.1505
OSC-19	GDSC1	-3.2105	0.3722	-3.3165	53.4652
PE/CA-PJ34 (clone C12)	CTRP2	-3.0472	0.4162	-3.057	60.3592
FaDu	GDSC1; CTRP2	-2.9844	-1.0611	-2.9845	60.145
CAL-33	GDSC1; CTRP2	-2.8893	1.3294	-2.9256	59.1102
PE/CA-PJ15	GDSC1; CTRP2	-2.8118	1.8647	-2.8772	58.455
PCI-15A	GDSC1	-2.6834	0.4543	-2.7668	48.7254
BICR 22	GDSC1; CTRP2	-2.5598	1.7348	-2.6071	56.9988
SCC-25	GDSC1; CTRP2	-2.4614	1.1549	-2.4801	56.5205
BICR 78	GDSC1	-2.4323	0.2785	-2.4836	46.3303
SCC-15	GDSC1	-2.1309	0.9186	-2.2388	43.6175
YD-10B	CTRP2	-2.0328	0.6716	-2.0363	53.7939
SCC-9	GDSC1; CTRP2	-1.9058	3.973	-2.1668	52.6255
PE/CA-PJ49	CTRP2	-1.8002	1.1248	-1.8076	52.2458
DOK	GDSC1	-1.6772	3.9266	-2.566	41.5458
SCC-4	GDSC1; CTRP2	-1.577	2.6077	-1.6454	50.7453
SNU-899	CTRP2	-1.5232	0.8894	-1.5254	50.4152
JHU-022	GDSC1	-1.4006	2.7097	-1.8528	37.9786
SNU-1076	CTRP2	-1.3512	1.076	-1.354	49.2723
BICR 6	CTRP2	-1.3491	5.3617	-1.8486	49.3736
UPCI-SCC-090	GDSC1	-1.2557	3.4076	-1.9248	37.4271
Detroit 562	GDSC1; CTRP2	-1.2516	2.7326	-1.3153	48.6508
BICR 31	GDSC1; CTRP2	-1.1771	5.3206	-1.6514	48.3879
PCI-30	GDSC1	-1.1229	4.5511	-2.2158	37.6406
PCI-38	GDSC1	-0.9721	1.5577	-1.0969	32.6163
YD-8	CTRP2	-0.9188	3.7755	-1.077	46.6012
BICR 18	CTRP2	-0.8846	3.6034	-1.0175	46.354
SNU-1066	CTRP2	-0.5677	2.6765	-0.6009	44.1286
BICR 16	CTRP2	-0.4898	1.1061	-0.49	43.5321
SAT [Human HNSCC]	GDSC1	-0.1609	3.461	-0.7659	27.2025
SNU-1214	CTRP2	0.4096	2.5922	0.4028	37.5621
SKN-3	GDSC1	0.4174	1.9498	0.3319	18.9411
SNU-46	CTRP2	0.4791	4.03	0.379	37.3842
BICR 56	CTRP2	0.4838	5.582	0.0957	38.1314
BICR 10	GDSC1	0.4979	4.1188	-0.3385	22.2119
LB771-HNC	GDSC1	0.5679	7.1437	-1.671	28.2866
PE/CA-PJ41 (clone D2)	CTRP2	0.6302	9.782	-1.1821	40.1171
SNU-1041	CTRP2	2.2484	6.4268	1.7913	26.8687

Cancer Drug Sensitivity Data Curated from 24 Cell Line(s) in Urinary Tract Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
BFTC-905	GDSC1; CTRP2	-5.2416	-3.1093	-5.2417	75.0515
647V	GDSC1; CTRP2	-4.5976	-2.3363	-4.5977	70.8013
SW1710	GDSC1; CTRP2	-4.4055	-0.9068	-4.4099	69.0449
RT-112	GDSC1; CTRP2	-4.3775	-1.2886	-4.3792	69.0863
639V	GDSC1; CTRP2	-4.3678	-1.7338	-4.3682	69.1981
5637	GDSC1; CTRP2	-3.6613	-0.6737	-3.6635	64.4869
UM-UC-3	GDSC1; CTRP2	-3.3865	-0.8851	-3.3871	62.7758
CAL-29	GDSC1; CTRP2	-2.8644	0.0625	-2.8677	59.2719
J82	GDSC1; CTRP2	-2.834	4.5543	-3.2825	57.3398
HT-1197	GDSC1; CTRP2	-2.0106	1.2577	-2.0238	53.6155
VM-CUB-1	CTRP2	-1.7422	2.2484	-1.7914	51.8159
SCaBER	CTRP2	-1.6693	3.2274	-1.805	51.2969
253J	CTRP2	-1.5516	0.2797	-1.5518	50.6057
JMSU-1	CTRP2	-1.3351	0.6322	-1.3356	49.1638
RT-4	GDSC1; CTRP2	-0.9705	0.9445	-0.9711	46.7356
TCCSUP	GDSC1; CTRP2	-0.8019	3.776	-0.9522	45.8474
KU-19-19	GDSC1; CTRP2	-0.7412	0.8077	-0.7413	45.207
SW780	GDSC1	-0.4947	0.5982	-0.4981	27.3953
U-BLC1	CTRP2	-0.2929	6.9441	-1.1368	43.6882
253J-BV	CTRP2	0.2918	6.0537	-0.2362	39.6674
BC-3C	CTRP2	1.4377	3.073	1.4346	30.7008
HT-1376	GDSC1; CTRP2	1.4511	8.3073	0.2726	34.1704
KMBC-2	CTRP2	2.847	8.1567	1.8153	24.9813
T24	GDSC1; CTRP2	3.0757	12.5217	0.0902	29.7265

Cancer Drug Sensitivity Data Curated from 39 Cell Line(s) in Urogenital System Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
NT2-D1	GDSC1	-7.4673	-5.9705	-7.4673	92.5538
KGN	GDSC1	-7.3434	1.0258	-7.9026	74.0057
PA-1	GDSC1	-6.3955	-5.669	-6.3955	80.3358
HEY	GDSC1	-5.8746	-0.9454	-5.9879	82.4809
OVCA433	GDSC1	-5.1379	1.1087	-5.5229	74.3193
BPH-1	GDSC1	-5.0879	-1.7222	-5.112	70.0266
NCC-IT	GDSC1	-5.0551	0.0997	-5.5379	59.3401
SW954	GDSC1	-5.0167	-0.2437	-5.16	67.2075
NEC8	GDSC1	-5.0117	-3.1518	-5.012	71.0398
C-33 A	GDSC1	-4.8747	-2.4	-4.8784	69.2897
DoTc2 4510	GDSC1	-4.6299	-1.3488	-4.658	66.2343
Ca Ski	GDSC1	-4.5557	-0.9241	-4.6064	65.1799
SW962	GDSC1	-4.2114	-0.4274	-4.2873	62.0863
SiSo	GDSC1	-4.1682	-2.3093	-4.1689	62.9978
C-4-I	GDSC1	-3.6444	-0.3759	-3.6974	57.4837
HT-3	GDSC1	-3.5166	-0.3493	-3.566	56.3687
OVMIU	GDSC1	-3.4427	0.6308	-3.6012	55.3144
PEO1	GDSC1	-3.0885	2.3934	-3.6023	61.5508
CAL-39	GDSC1	-3.082	0.2511	-3.1657	52.3627
JEG-3	GDSC1	-3.0014	-0.4283	-3.026	51.7017
SKN	GDSC1	-2.8654	1.0505	-3.0496	50.3781
ME-180	GDSC1	-2.6156	0.2615	-2.6746	48.0719
TC-YIK	GDSC1	-2.6019	-0.0375	-2.6357	60.751
HEC-1	GDSC1	-2.4144	0.8909	-2.5383	46.2926
OV17R	GDSC1	-2.1305	7.5685	-4.5486	52.3988
LB831-BLC	GDSC1	-2.0892	0.3674	-2.1316	43.0289
PWR-1E	GDSC1	-2.0187	4.7804	-3.2565	52.4217
OMC-1 [Human cervical carcinoma]	GDSC1	-2.0074	4.5756	-3.1647	44.5113
SW756	GDSC1	-1.991	0.5669	-2.047	42.1319
JHOS-3	GDSC1	-1.9303	3.2571	-2.604	52.1734
DSH1	GDSC1	-1.9181	1.3521	-2.0812	41.7825
HeLa	GDSC1; CTRP2	-1.6535	2.0559	-1.6884	51.2544
MS751	GDSC1	-1.6494	0.8649	-1.7185	38.8992
SKG-IIIa	GDSC1	-1.5296	3.4116	-2.2223	39.8483
ACC-OV7	GDSC1	-1.4834	2.3606	-1.8416	48.0161
JAR	GDSC1	-1.1684	0.2404	-1.1739	33.9537
OVCA420	GDSC1	-1.1528	4.1598	-2.0929	45.5514
UWB1.289	GDSC1	-0.8708	4.9411	-2.111	43.5836
SiHa	GDSC1	0.1956	1.3679	0.1761	20.7644

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Doxorubicin

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Larotrectinib	DM26CQR	Moderate	Decreased metabolism of Doxorubicin caused by Larotrectinib mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[35]
Ifosfamide	DMCT3I8	Moderate	Additive myelosuppressive effects by the combination of Doxorubicin and Ifosfamide.	Solid tumour/cancer [2A00-2F9Z]	[36]
Armodafinil	DMGB035	Minor	Increased metabolism of Doxorubicin caused by Armodafinil mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[37]
LEE011	DMMX75K	Major	Decreased metabolism of Doxorubicin caused by LEE011 mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[38]
Vandetanib	DMRICNP	Major	Increased risk of prolong QT interval by the combination of Doxorubicin and Vandetanib.	Solid tumour/cancer [2A00-2F9Z]	[38]
Triptorelin	DMTK4LS	Moderate	Increased risk of prolong QT interval by the combination of Doxorubicin and Triptorelin.	Solid tumour/cancer [2A00-2F9Z]	[39]

Coadministration of a Drug Treating the Disease Different from Doxorubicin (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Metreleptin	DM1NOEK	Moderate	Increased metabolism of Doxorubicin caused by Metreleptin mediated induction of CYP450 enzyme.	Acute diabete complication [5A2Y]	[39]
Ivosidenib	DM8S6T7	Major	Increased risk of prolong QT interval by the combination of Doxorubicin and Ivosidenib.	Acute myeloid leukaemia [2A60]	[40]
Midostaurin	DMI6E0R	Moderate	Increased risk of prolong QT interval by the combination of Doxorubicin and Midostaurin.	Acute myeloid leukaemia [2A60]	[38]
Idarubicin	DMM0XGL	Moderate	Increased risk of prolong QT interval by the combination of Doxorubicin and Idarubicin.	Acute myeloid leukaemia [2A60]	[38]
Arn-509	DMT81LZ	Moderate	Increased metabolism of Doxorubicin caused by Arn-509 mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[39]
Gilteritinib	DMTI0ZO	Moderate	Increased risk of prolong QT interval by the combination of Doxorubicin and Gilteritinib.	Acute myeloid leukaemia [2A60]	[41]
Oliceridine	DM6MDCF	Moderate	Increased risk of prolong QT interval by the combination of Doxorubicin and Oliceridine.	Acute pain [MG31]	[38]
Ivabradine	DM0L594	Major	Increased risk of ventricular arrhythmias by the combination of Doxorubicin and Ivabradine.	Angina pectoris [BA40]	[39]
Bepridil	DM0RKS4	Major	Increased risk of prolong QT interval by the combination of Doxorubicin and Bepridil.	Angina pectoris [BA40]	[38]
Dronedarone	DMA8FS5	Major	Increased risk of prolong QT interval by the combination of Doxorubicin and Dronedarone.	Angina pectoris [BA40]	[38]
Bedaquiline	DM3906J	Major	Increased risk of prolong QT interval by the combination of Doxorubicin and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[42]
Cilostazol	DMZMSCT	Moderate	Increased risk of prolong QT interval by the combination of Doxorubicin and Cilostazol.	Arterial occlusive disease [BD40]	[38]
Posaconazole	DMUL5EW	Moderate	Decreased metabolism of Doxorubicin caused by Posaconazole mediated inhibition of CYP450 enzyme.	Aspergillosis [1F20]	[39]
Levalbuterol	DM5YBO1	Moderate	Increased risk of ventricular arrhythmias by the combination of Doxorubicin and Levalbuterol.	Asthma [CA23]	[43]
Pirbuterol	DMI5678	Moderate	Increased risk of prolong QT interval by the combination of Doxorubicin and Pirbuterol.	Asthma [CA23]	[44]
Salbutamol	DMN9CWF	Moderate	Increased risk of ventricular arrhythmias by the combination of Doxorubicin and Salbutamol.	Asthma [CA23]	[43]
Roflumilast	DMPGHY8	Moderate	Additive immunosuppressive effects by the combination of Doxorubicin and Roflumilast.	Asthma [CA23]	[39]
Lisdexamfetamine	DM6W8V5	Moderate	Increased risk of prolong QT interval by the combination of Doxorubicin and Lisdexamfetamine.	Attention deficit hyperactivity disorder [6A05]	[39]
Desipramine	DMT2FDC	Moderate	Increased risk of prolong QT interval by the combination of Doxorubicin and Desipramine.	Attention deficit hyperactivity disorder [6A05]	[38]
Ofloxacin	DM0VQN3	Moderate	Increased risk of prolong QT interval by the combination of Doxorubicin and Ofloxacin.	Bacterial infection [1A00-1C4Z]	[45]
Dalfopristin	DM4LTKV	Major	Decreased metabolism of Doxorubicin caused by Dalfopristin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[46]
Clarithromycin	DM4M1SG	Moderate	Increased risk of prolong QT interval by the combination of Doxorubicin and Clarithromycin.	Bacterial infection [1A00-1C4Z]	[47]
Sulfamethoxazole	DMB08GE	Minor	Increased risk of prolong QT interval by the combination of Doxorubicin and Sulfamethoxazole.	Bacterial infection [1A00-1C4Z]	[38]
Sparfloxacin	DMB4HCT	Major	Increased risk of prolong QT interval by the combination of Doxorubicin and Sparfloxacin.	Bacterial infection [1A00-1C4Z]	[45]
Gemifloxacin	DMHT34O	Moderate	Increased risk of prolong QT interval by the combination of Doxorubicin and Gemifloxacin.	Bacterial infection [1A00-1C4Z]	[45]
Norfloxacin	DMIZ6W2	Moderate	Increased risk of prolong QT interval by the combination of Doxorubicin and Norfloxacin.	Bacterial infection [1A00-1C4Z]	[45]
ABT-492	DMJFD2I	Minor	Decreased absorption of Doxorubicin due to intestinal mucosa variation caused by ABT-492.	Bacterial infection [1A00-1C4Z]	[48]
Levofloxacin	DMS60RB	Moderate	Increased risk of prolong QT interval by the combination of Doxorubicin and Levofloxacin.	Bacterial infection [1A00-1C4Z]	[45]
Ag-221	DMS0ZBI	Moderate	Decreased clearance of Doxorubicin due to the transporter inhibition by Ag-221.	BCR-ABL1-negative chronic myeloid leukaemia [2A41]	[35]
Retigabine	DMGNYIH	Moderate	Increased risk of prolong QT interval by the combination of Doxorubicin and Retigabine.	Behcet disease [4A62]	[38]
Erdafitinib	DMI782S	Moderate	Decreased clearance of Doxorubicin due to the transporter inhibition by Erdafitinib.	Bladder cancer [2C94]	[49]
Pexidartinib	DMS2J0Z	Moderate	Increased metabolism of Doxorubicin caused by Pexidartinib mediated induction of CYP450 enzyme.	Bone/articular cartilage neoplasm [2F7B]	[39]
Eribulin	DM1DX4Q	Moderate	Increased risk of prolong QT interval by the combination of Doxorubicin and Eribulin.	Breast cancer [2C60-2C6Y]	[38]
Lapatinib	DM3BH1Y	Moderate	Increased risk of prolong QT interval by the combination of Doxorubicin and Lapatinib.	Breast cancer [2C60-2C6Y]	[47]
Tucatinib	DMBESUA	Moderate	Decreased metabolism of Doxorubicin caused by Tucatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[50]
PF-04449913	DMSB068	Moderate	Increased risk of prolong QT interval by the combination of Doxorubicin and PF-04449913.	Chronic myelomonocytic leukaemia [2A40]	[51]
Olodaterol	DM62B78	Moderate	Increased risk of prolong QT interval by the combination of Doxorubicin and Olodaterol.	Chronic obstructive pulmonary disease [CA22]	[44]
Vilanterol	DMF5EK1	Moderate	Increased risk of prolong QT interval by the combination of Doxorubicin and Vilanterol.	Chronic obstructive pulmonary disease [CA22]	[43]
Indacaterol	DMQJHR7	Moderate	Increased risk of ventricular arrhythmias by the combination of Doxorubicin and Indacaterol.	Chronic obstructive pulmonary disease [CA22]	[44]
Arformoterol	DMYM974	Moderate	Increased risk of prolong QT interval by the combination of Doxorubicin and Arformoterol.	Chronic obstructive pulmonary disease [CA22]	[44]
Isoproterenol	DMK7MEY	Moderate	Increased risk of ventricular arrhythmias by the combination of Doxorubicin and Isoproterenol.	Conduction disorder [BC63]	[43]
Halothane	DM80OZ5	Moderate	Increased risk of prolong QT interval by the combination of Doxorubicin and Halothane.	Corneal disease [9A76-9A78]	[38]
Sevoflurane	DMC9O43	Moderate	Increased risk of prolong QT interval by the combination of Doxorubicin and Sevoflurane.	Corneal disease [9A76-9A78]	[38]
Probucol	DMVZQ2M	Moderate	Increased risk of prolong QT interval by the combination of Doxorubicin and Probucol.	Coronary atherosclerosis [BA80]	[38]
Pasireotide	DMHM7JS	Major	Increased risk of prolong QT interval by the combination of Doxorubicin and Pasireotide.	Cushing syndrome [5A70]	[38]
Osilodrostat	DMIJC9X	Moderate	Increased risk of prolong QT interval by the combination of Doxorubicin and Osilodrostat.	Cushing syndrome [5A70]	[39]
Lumacaftor	DMCLWDJ	Moderate	Increased metabolism of Doxorubicin caused by Lumacaftor mediated induction of CYP450 enzyme.	Cystic fibrosis [CA25]	[52]
Ivacaftor	DMZC1HS	Moderate	Decreased metabolism of Doxorubicin caused by Ivacaftor mediated inhibition of CYP450 enzyme.	Cystic fibrosis [CA25]	[53]
MK-8228	DMOB58Q	Moderate	Decreased metabolism of Doxorubicin caused by MK-8228 mediated inhibition of CYP450 enzyme.	Cytomegaloviral disease [1D82]	[54]
Sertraline	DM0FB1J	Moderate	Increased risk of prolong QT interval by the combination of Doxorubicin and Sertraline.	Depression [6A70-6A7Z]	[38]
Nefazodone	DM4ZS8M	Moderate	Decreased metabolism of Doxorubicin caused by Nefazodone mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[55]
Escitalopram	DMFK9HG	Major	Increased risk of prolong QT interval by the combination of Doxorubicin and Escitalopram.	Depression [6A70-6A7Z]	[38]
Clomipramine	DMINRKW	Moderate	Increased risk of prolong QT interval by the combination of Doxorubicin and Clomipramine.	Depression [6A70-6A7Z]	[38]
Doxepin	DMPI98T	Moderate	Increased risk of prolong QT interval by the combination of Doxorubicin and Doxepin.	Depression [6A70-6A7Z]	[38]
Tetrabenazine	DMYWQ0O	Moderate	Increased risk of prolong QT interval by the combination of Doxorubicin and Tetrabenazine.	Dissociative neurological symptom disorder [6B60]	[38]
Deutetrabenazine	DMUPFLI	Moderate	Additive CNS depression effects by the combination of Doxorubicin and Deutetrabenazine.	Dystonic disorder [8A02]	[56]
Ingrezza	DMVPLNC	Moderate	Increased risk of prolong QT interval by the combination of Doxorubicin and Ingrezza.	Dystonic disorder [8A02]	[57]
Cenobamate	DM8KLU9	Moderate	Increased metabolism of Doxorubicin caused by Cenobamate mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[39]
Stiripentol	DMMSDOY	Moderate	Decreased metabolism of Doxorubicin caused by Stiripentol mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[58]
Rufinamide	DMWE60C	Moderate	Increased metabolism of Doxorubicin caused by Rufinamide mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[39]
Phenobarbital	DMXZOCG	Moderate	Increased metabolism of Doxorubicin caused by Phenobarbital mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[39]
Eslicarbazepine	DMZREFQ	Moderate	Increased metabolism of Doxorubicin caused by Eslicarbazepine mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[39]
Tazemetostat	DMWP1BH	Moderate	Increased metabolism of Doxorubicin caused by Tazemetostat mediated induction of CYP450 enzyme.	Follicular lymphoma [2A80]	[59]
Solifenacin	DMG592Q	Moderate	Increased risk of prolong QT interval by the combination of Doxorubicin and Solifenacin.	Functional bladder disorder [GC50]	[38]
Itraconazole	DMCR1MV	Moderate	Decreased metabolism of Doxorubicin caused by Itraconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[60]
Ketoconazole	DMPZI3Q	Moderate	Increased risk of prolong QT interval by the combination of Doxorubicin and Ketoconazole.	Fungal infection [1F29-1F2F]	[38]
Sunitinib	DMCBJSR	Moderate	Increased risk of prolong QT interval by the combination of Doxorubicin and Sunitinib.	Gastrointestinal stromal tumour [2B5B]	[38]
Sulfinpyrazone	DMEV954	Moderate	Increased metabolism of Doxorubicin caused by Sulfinpyrazone mediated induction of CYP450 enzyme.	Gout [FA25]	[39]
Rifampin	DMA8J1G	Moderate	Increased metabolism of Doxorubicin caused by Rifampin mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[52]
Rifapentine	DMCHV4I	Moderate	Increased metabolism of Doxorubicin caused by Rifapentine mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[39]
Fostemsavir	DM50ILT	Moderate	Increased risk of prolong QT interval by the combination of Doxorubicin and Fostemsavir.	Human immunodeficiency virus disease [1C60-1C62]	[61]
Saquinavir	DMG814N	Major	Increased risk of prolong QT interval by the combination of Doxorubicin and Saquinavir.	Human immunodeficiency virus disease [1C60-1C62]	[62]
Etravirine	DMGV8QU	Moderate	Increased metabolism of Doxorubicin caused by Etravirine mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[39]
Rilpivirine	DMJ0QOW	Moderate	Increased risk of prolong QT interval by the combination of Doxorubicin and Rilpivirine.	Human immunodeficiency virus disease [1C60-1C62]	[38]
Darunavir	DMN3GCH	Moderate	Decreased metabolism of Doxorubicin caused by Darunavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[63]
Teriflunomide	DMQ2FKJ	Major	Additive myelosuppressive effects by the combination of Doxorubicin and Teriflunomide.	Hyper-lipoproteinaemia [5C80]	[64]
BMS-201038	DMQTAGO	Moderate	Decreased clearance of Doxorubicin due to the transporter inhibition by BMS-201038.	Hyper-lipoproteinaemia [5C80]	[65]
Tolvaptan	DMIWFRL	Moderate	Decreased clearance of Doxorubicin due to the transporter inhibition by Tolvaptan.	Hypo-osmolality/hyponatraemia [5C72]	[35]
Givosiran	DM5PFIJ	Moderate	Decreased metabolism of Doxorubicin caused by Givosiran mediated inhibition of CYP450 enzyme.	Inborn porphyrin/heme metabolism error [5C58]	[66]
Berotralstat	DMWA2DZ	Moderate	Decreased metabolism of Doxorubicin caused by Berotralstat mediated inhibition of CYP450 enzyme.	Innate/adaptive immunodeficiency [4A00]	[67]
Amobarbital	DM0GQ8N	Moderate	Increased metabolism of Doxorubicin caused by Amobarbital mediated induction of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[39]
Polyethylene glycol	DM4I1JP	Moderate	Increased risk of ventricular arrhythmias by the combination of Doxorubicin and Polyethylene glycol.	Irritable bowel syndrome [DD91]	[39]
Denosumab	DMNI0KO	Moderate	Additive immunosuppressive effects by the combination of Doxorubicin and Denosumab.	Low bone mass disorder [FB83]	[68]
Crizotinib	DM4F29C	Major	Increased risk of prolong QT interval by the combination of Doxorubicin and Crizotinib.	Lung cancer [2C25]	[69]
Brigatinib	DM7W94S	Moderate	Increased metabolism of Doxorubicin caused by Brigatinib mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[39]
Ceritinib	DMB920Z	Major	Increased risk of prolong QT interval by the combination of Doxorubicin and Ceritinib.	Lung cancer [2C25]	[38]
PF-06463922	DMKM7EW	Moderate	Increased metabolism of Doxorubicin caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[52]
Dacomitinib	DMOH8VY	Moderate	Decreased metabolism of Doxorubicin caused by Dacomitinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[70]
Osimertinib	DMRJLAT	Major	Increased risk of prolong QT interval by the combination of Doxorubicin and Osimertinib.	Lung cancer [2C25]	[71]
Capmatinib	DMYCXKL	Moderate	Decreased clearance of Doxorubicin due to the transporter inhibition by Capmatinib.	Lung cancer [2C25]	[72]
Selpercatinib	DMZR15V	Major	Increased risk of prolong QT interval by the combination of Doxorubicin and Selpercatinib.	Lung cancer [2C25]	[39]
Lumefantrine	DM29GAD	Major	Increased risk of prolong QT interval by the combination of Doxorubicin and Lumefantrine.	Malaria [1F40-1F45]	[35]
Halofantrine	DMOMK1V	Major	Increased risk of prolong QT interval by the combination of Doxorubicin and Halofantrine.	Malaria [1F40-1F45]	[73]
Hydroxychloroquine	DMSIVND	Major	Increased risk of prolong QT interval by the combination of Doxorubicin and Hydroxychloroquine.	Malaria [1F40-1F45]	[74]
Primaquine	DMWQ16I	Moderate	Increased risk of prolong QT interval by the combination of Doxorubicin and Primaquine.	Malaria [1F40-1F45]	[38]
Inotuzumab ozogamicin	DMAC130	Moderate	Increased risk of prolong QT interval by the combination of Doxorubicin and Inotuzumab ozogamicin.	Malignant haematopoietic neoplasm [2B33]	[39]
Idelalisib	DM602WT	Moderate	Decreased metabolism of Doxorubicin caused by Idelalisib mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[75]
IPI-145	DMWA24P	Moderate	Decreased metabolism of Doxorubicin caused by IPI-145 mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[76]
Arsenic trioxide	DM61TA4	Major	Increased risk of prolong QT interval by the combination of Doxorubicin and Arsenic trioxide.	Mature B-cell lymphoma [2A85]	[77]
Mercaptopurine	DMTM2IK	Moderate	Increased risk of hepatotoxicity by the combination of Doxorubicin and Mercaptopurine.	Mature B-cell lymphoma [2A85]	[36]
Vemurafenib	DM62UG5	Major	Increased risk of prolong QT interval by the combination of Doxorubicin and Vemurafenib.	Melanoma [2C30]	[38]
LGX818	DMNQXV8	Moderate	Increased risk of prolong QT interval by the combination of Doxorubicin and LGX818.	Melanoma [2C30]	[78]
Dabrafenib	DMX6OE3	Moderate	Increased metabolism of Doxorubicin caused by Dabrafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[39]
Lasmiditan	DMXLVDT	Moderate	Decreased clearance of Doxorubicin due to the transporter inhibition by Lasmiditan.	Migraine [8A80]	[79]
Exjade	DMHPRWG	Moderate	Increased metabolism of Doxorubicin caused by Exjade mediated induction of CYP450 enzyme.	Mineral absorption/transport disorder [5C64]	[39]
Panobinostat	DM58WKG	Major	Increased risk of prolong QT interval by the combination of Doxorubicin and Panobinostat.	Multiple myeloma [2A83]	[80]
Thalidomide	DM70BU5	Major	Additive thrombogenic effects by the combination of Doxorubicin and Thalidomide.	Multiple myeloma [2A83]	[81]
Tecfidera	DM2OVDT	Moderate	Additive immunosuppressive effects by the combination of Doxorubicin and Tecfidera.	Multiple sclerosis [8A40]	[82]
Siponimod	DM2R86O	Major	Additive immunosuppressive effects by the combination of Doxorubicin and Siponimod.	Multiple sclerosis [8A40]	[35]
Fingolimod	DM5JVAN	Major	Increased risk of ventricular arrhythmias by the combination of Doxorubicin and Fingolimod.	Multiple sclerosis [8A40]	[83]
Ocrelizumab	DMEZ2KH	Moderate	Additive immunosuppressive effects by the combination of Doxorubicin and Ocrelizumab.	Multiple sclerosis [8A40]	[84]
Ozanimod	DMT6AM2	Major	Increased risk of ventricular arrhythmias by the combination of Doxorubicin and Ozanimod.	Multiple sclerosis [8A40]	[39]
Romidepsin	DMT5GNL	Moderate	Increased risk of prolong QT interval by the combination of Doxorubicin and Romidepsin.	Mycosis fungoides [2B01]	[38]
Fedratinib	DM4ZBK6	Moderate	Decreased metabolism of Doxorubicin caused by Fedratinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[39]
Nilotinib	DM7HXWT	Major	Increased risk of prolong QT interval by the combination of Doxorubicin and Nilotinib.	Myeloproliferative neoplasm [2A20]	[38]
Dasatinib	DMJV2EK	Moderate	Increased risk of prolong QT interval by the combination of Doxorubicin and Dasatinib.	Myeloproliferative neoplasm [2A20]	[85]
Omacetaxine mepesuccinate	DMPU2WX	Moderate	Additive myelosuppressive effects by the combination of Doxorubicin and Omacetaxine mepesuccinate.	Myeloproliferative neoplasm [2A20]	[86]
Promethazine	DM6I5GR	Moderate	Increased risk of prolong QT interval by the combination of Doxorubicin and Promethazine.	Nausea/vomiting [MD90]	[38]
Rolapitant	DM8XP26	Moderate	Decreased clearance of Doxorubicin due to the transporter inhibition by Rolapitant.	Nausea/vomiting [MD90]	[87]
Entrectinib	DMMPTLH	Moderate	Increased risk of prolong QT interval by the combination of Doxorubicin and Entrectinib.	Non-small cell lung cancer [2C25]	[35]
Levomethadyl Acetate	DM06HG5	Major	Increased risk of prolong QT interval by the combination of Doxorubicin and Levomethadyl Acetate.	Opioid use disorder [6C43]	[39]
Lofexidine	DM1WXA6	Moderate	Increased risk of prolong QT interval by the combination of Doxorubicin and Lofexidine.	Opioid use disorder [6C43]	[38]
Rucaparib	DM9PVX8	Moderate	Decreased metabolism of Doxorubicin caused by Rucaparib mediated inhibition of CYP450 enzyme.	Ovarian cancer [2C73]	[88]
Triclabendazole	DMPWGBR	Moderate	Increased risk of prolong QT interval by the combination of Doxorubicin and Triclabendazole.	Parasitic worm infestation [1F90]	[38]
Pimavanserin	DMR7IVC	Moderate	Increased risk of prolong QT interval by the combination of Doxorubicin and Pimavanserin.	Parkinsonism [8A00]	[89]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Doxorubicin caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[90]
Macimorelin	DMQYJIR	Major	Increased risk of prolong QT interval by the combination of Doxorubicin and Macimorelin.	Pituitary gland disorder [5A60-5A61]	[91]
Lefamulin	DME6G97	Major	Increased risk of prolong QT interval by the combination of Doxorubicin and Lefamulin.	Pneumonia [CA40]	[92]
Lonafarnib	DMGM2Z6	Moderate	Decreased metabolism of Doxorubicin caused by Lonafarnib mediated inhibition of CYP450 enzyme.	Premature ageing appearance [LD2B]	[93]
Degarelix	DM3O8QY	Moderate	Increased risk of prolong QT interval by the combination of Doxorubicin and Degarelix.	Prostate cancer [2C82]	[39]
ABIRATERONE	DM8V75C	Moderate	Increased risk of prolong QT interval by the combination of Doxorubicin and ABIRATERONE.	Prostate cancer [2C82]	[39]
Enzalutamide	DMGL19D	Moderate	Increased metabolism of Doxorubicin caused by Enzalutamide mediated induction of CYP450 enzyme.	Prostate cancer [2C82]	[39]
Relugolix	DMK7IWL	Moderate	Increased risk of prolong QT interval by the combination of Doxorubicin and Relugolix.	Prostate cancer [2C82]	[39]
Darolutamide	DMV7YFT	Moderate	Decreased clearance of Doxorubicin due to the transporter inhibition by Darolutamide.	Prostate cancer [2C82]	[94]
Bicalutamide	DMZMSPF	Moderate	Increased risk of prolong QT interval by the combination of Doxorubicin and Bicalutamide.	Prostate cancer [2C82]	[39]
Levomepromazine	DMIKFEL	Moderate	Increased risk of prolong QT interval by the combination of Doxorubicin and Levomepromazine.	Psychotic disorder [6A20-6A25]	[38]
Temsirolimus	DMS104F	Moderate	Increased plasma concentrations of Doxorubicin and Temsirolimus due to competitive inhibition of the same metabolic pathway.	Renal cell carcinoma [2C90]	[95]
Gatifloxacin	DMSL679	Major	Increased risk of prolong QT interval by the combination of Doxorubicin and Gatifloxacin.	Respiratory infection [CA07-CA4Z]	[96]
Canakinumab	DM8HLO5	Moderate	Additive immunosuppressive effects by the combination of Doxorubicin and Canakinumab.	Rheumatoid arthritis [FA20]	[97]
Rilonacept	DMGLUQS	Moderate	Additive immunosuppressive effects by the combination of Doxorubicin and Rilonacept.	Rheumatoid arthritis [FA20]	[97]
Golimumab	DMHZV7X	Major	Additive immunosuppressive effects by the combination of Doxorubicin and Golimumab.	Rheumatoid arthritis [FA20]	[98]
Dexamethasone	DMMWZET	Moderate	Increased metabolism of Doxorubicin caused by Dexamethasone mediated induction of CYP450 enzyme.	Rheumatoid arthritis [FA20]	[39]
Leflunomide	DMR8ONJ	Major	Additive immunosuppressive effects by the combination of Doxorubicin and Leflunomide.	Rheumatoid arthritis [FA20]	[64]
Quetiapine	DM1N62C	Moderate	Increased risk of prolong QT interval by the combination of Doxorubicin and Quetiapine.	Schizophrenia [6A20]	[38]
Aripiprazole	DM3NUMH	Moderate	Increased risk of prolong QT interval by the combination of Doxorubicin and Aripiprazole.	Schizophrenia [6A20]	[35]
Iloperidone	DM6AUFY	Major	Increased risk of prolong QT interval by the combination of Doxorubicin and Iloperidone.	Schizophrenia [6A20]	[38]
Paliperidone	DM7NPJS	Moderate	Increased risk of prolong QT interval by the combination of Doxorubicin and Paliperidone.	Schizophrenia [6A20]	[38]
Amisulpride	DMSJVAM	Major	Increased risk of prolong QT interval by the combination of Doxorubicin and Amisulpride.	Schizophrenia [6A20]	[99]
Asenapine	DMSQZE2	Moderate	Increased risk of prolong QT interval by the combination of Doxorubicin and Asenapine.	Schizophrenia [6A20]	[38]
Pimozide	DMW83TP	Major	Increased risk of prolong QT interval by the combination of Doxorubicin and Pimozide.	Schizophrenia [6A20]	[39]
Anthrax vaccine	DM9GSWY	Moderate	Antagonize the effect of Doxorubicin when combined with Anthrax vaccine.	Sepsis [1G40-1G41]	[100]
Voxelotor	DMCS6M5	Moderate	Decreased metabolism of Doxorubicin caused by Voxelotor mediated inhibition of CYP450 enzyme.	Sickle-cell disorder [3A51]	[101]
Telotristat ethyl	DMDIYFZ	Moderate	Increased metabolism of Doxorubicin caused by Telotristat ethyl mediated induction of CYP450 enzyme.	Small intestine developmental anomaly [DA90]	[39]
Pitolisant	DM8RFNJ	Moderate	Increased risk of prolong QT interval by the combination of Doxorubicin and Pitolisant.	Somnolence [MG42]	[39]
Telavancin	DM58VQX	Moderate	Increased risk of prolong QT interval by the combination of Doxorubicin and Telavancin.	Staphylococcal/streptococcal disease [1B5Y]	[38]
Fostamatinib	DM6AUHV	Moderate	Decreased metabolism of Doxorubicin caused by Fostamatinib mediated inhibition of CYP450 enzyme.	Thrombocytopenia [3B64]	[102]
Lenvatinib	DMB1IU4	Moderate	Increased risk of prolong QT interval by the combination of Doxorubicin and Lenvatinib.	Thyroid cancer [2D10]	[38]
Cabozantinib	DMIYDT4	Major	Increased risk of prolong QT interval by the combination of Doxorubicin and Cabozantinib.	Thyroid cancer [2D10]	[39]
Papaverine	DMCA9QP	Major	Increased risk of prolong QT interval by the combination of Doxorubicin and Papaverine.	Tonus and reflex abnormality [MB47]	[103]
Trimeprazine	DMEMV9D	Moderate	Increased risk of prolong QT interval by the combination of Doxorubicin and Trimeprazine.	Vasomotor/allergic rhinitis [CA08]	[47]
Procainamide	DMNMXR8	Major	Increased risk of prolong QT interval by the combination of Doxorubicin and Procainamide.	Ventricular tachyarrhythmia [BC71]	[38]
Propafenone	DMPIBJK	Moderate	Increased risk of prolong QT interval by the combination of Doxorubicin and Propafenone.	Ventricular tachyarrhythmia [BC71]	[38]
Flecainide	DMSQDLE	Moderate	Increased risk of prolong QT interval by the combination of Doxorubicin and Flecainide.	Ventricular tachyarrhythmia [BC71]	[38]
Amiodarone	DMUTEX3	Major	Increased risk of prolong QT interval by the combination of Doxorubicin and Amiodarone.	Ventricular tachyarrhythmia [BC71]	[38]
Ganciclovir	DM1MBYQ	Moderate	Additive myelosuppressive effects by the combination of Doxorubicin and Ganciclovir.	Virus infection [1A24-1D9Z]	[35]
Valganciclovir	DMS2IUH	Moderate	Additive myelosuppressive effects by the combination of Doxorubicin and Valganciclovir.	Virus infection [1A24-1D9Z]	[35]

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Histidine	E00106	6274	Antioxidant; Buffering agent
Hydrochloric acid	E00015	313	Acidulant
Ammonium sulfate	E00490	6097028	Buffering agent
Cholesterol	E00092	5997	Emollient; Emulsifying agent
Saccharose	E00091	5988	Binding agent; Coating agent; Cryoprotectant; Diluent; Flavoring agent; Suspending agent; Viscosity-controlling agent
Sodium chloride	E00077	5234	Diluent; Tonicity agent
Sodium hydroxide	E00234	14798	Alkalizing agent
Soybean lecithin	E00637	Not Available	Other agent
Water	E00035	962	Solvent
N-(carbonyl-methoxypolyethylene glycol 2000)-1	E00685	86278269	Other agent

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Doxorubicin Hydrochloride 20mg/10ml liposomaldispersion	20mg/10ml	Liposomaldispersion	Intravenous
Doxorubicin Hydrochloride 10mg/5ml solution	10mg/5ml	Solution	Intravenous
Doxorubicin Hydrochloride 20mg/10ml solution	20mg/10ml	Solution	Intravenous
Doxorubicin Hydrochloride 50mg/25ml solution	50mg/25ml	Solution	Intravenous

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

• [1] Doxorubicin FDA Label
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7069).
• [3] ClinicalTrials.gov (NCT02112656) Study of ThermoDox With Standardized Radiofrequency Ablation (RFA) for Treatment of Hepatocellular Carcinoma (HCC) (OPTIMA). U.S. National Institutes of Health.
• [4] Antitumor activity of liposome-encapsulated doxorubicin in advanced breast cancer: phase II study. J Natl Cancer Inst. 1990 Nov 7;82(21):1706-10.
• [5] Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207.
• [6] BDDCS applied to over 900 drugs
• [7] Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
• [8] Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
• [9] Recommendations for genetic testing to reduce the incidence of anthracycline-induced cardiotoxicity. Br J Clin Pharmacol. 2016 Sep;82(3):683-95. doi: 10.1111/bcp.13008. Epub 2016 Jun 30.
• [10] ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
• [11] Genome-wide association study of chemotherapeutic agent-induced severe neutropenia/leucopenia for patients in Biobank Japan. Cancer Sci. 2013 Aug;104(8):1074-82. doi: 10.1111/cas.12186. Epub 2013 Jun 10.
• [12] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [13] ABCB8 mediates doxorubicin resistance in melanoma cells by protecting the mitochondrial genome. Mol Cancer Res. 2009 Jan;7(1):79-87.
• [14] ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma. Cancer Res. 2005 May 15;65(10):4320-33.
• [15] Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide. Br J Cancer. 2010 Mar 16;102(6):1003-9.
• [16] Circadian rhythms in gene expression: Relationship to physiology, disease, drug disposition and drug action. Adv Drug Deliv Rev. 2010 Jul 31;62(9-10):904-17.
• [17] Involvement of the drug transporters p glycoprotein and multidrug resistance-associated protein Mrp2 in telithromycin transport. Antimicrob Agents Chemother. 2006 Jan;50(1):80-7.
• [18] The role of bioreductive activation of doxorubicin in cytotoxic activity against leukaemia HL60-sensitive cell line and its multidrug-resistant sublines. Br J Cancer. 2005 Jul 11;93(1):89-97.
• [19] Doxorubicin transport by RALBP1 and ABCG2 in lung and breast cancer. Int J Oncol. 2007 Mar;30(3):717-25.
• [20] MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
• [21] Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
• [22] Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
• [23] Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer. J Urol. 2008 Dec;180(6):2389-95.
• [24] Differential ability of cytostatics from anthraquinone group to generate free radicals in three enzymatic systems: NADH dehydrogenase, NADPH cytochrome P450 reductase, and xanthine oxidase. Oncol Res. 2003;13(5):245-52.
• [25] The role of nitric oxide in anthracycline toxicity and prospects for pharmacologic prevention of cardiac damage. FASEB J. 2004 Apr;18(6):664-75.
• [26] Kinetics of anthracycline antibiotic free radical formation and reductive glycosidase activity. Arch Biochem Biophys. 1983 May;223(1):68-75.
• [27] Inactivation of the anticancer drugs doxorubicin and oracin by aldo-keto reductase (AKR) 1C3. Toxicol Lett. 2008 Sep;181(1):1-6.
• [28] Carbonyl reductase 1 is a predominant doxorubicin reductase in the human liver. Drug Metab Dispos. 2008 Oct;36(10):2113-20.
• [29] Xanthine oxidoreductase in drug metabolism: beyond a role as a detoxifying enzyme. Curr Med Chem. 2016;23(35):4027-4036.
• [30] Differences in the efficiency of reductive activation of methionine synthase and exogenous electron acceptors between the common polymorphic variants of human methionine synthase reductase. Biochemistry. 2002 Nov 12;41(45):13378-85.
• [31] Naturally occurring variants of human aldo-keto reductases with reduced in vitro metabolism of daunorubicin and doxorubicin. J Pharmacol Exp Ther. 2010 Dec;335(3):533-45.
• [32] Bacterial inactivation of the anticancer drug doxorubicin. Chem Biol. 2012 Oct 26;19(10):1255-64.
• [33] Transformation of the anticancer drug doxorubicin in the human gut microbiome. ACS Infect Dis. 2018 Jan 12;4(1):68-76.
• [34] Bringing in vitro analysis closer to in vivo: studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling. Toxicol Lett. 2018 Sep 15;294:184-192.
• [35] Cerner Multum, Inc. "Australian Product Information.".
• [36] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
• [37] Doherty MM, Charman WN "The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?" Clin Pharmacokinet 41 (2002): 235-53. [PMID: 11978143]
• [38] Canadian Pharmacists Association.
• [39] Cerner Multum, Inc. "UK Summary of Product Characteristics.".
• [40] Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
• [41] Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
• [42] Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
• [43] Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
• [44] Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
• [45] Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9. [PMID: 10797074]
• [46] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77. [PMID: 11103749]
• [47] Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8. [PMID: 12904146]
• [48] Johnson EJ, MacGowan AP, Potter MN, et al "Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy." J Antimicrob Chemother 25 (1990): 837-42. [PMID: 2373666]
• [49] Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
• [50] Product Information. Tukysa (tucatinib). Seattle Genetics Inc, Bothell, WA.
• [51] Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
• [52] Product Information. Adriamycin PFS (doxorubicin). Pharmacia and Upjohn, Kalamazoo, MI.
• [53] Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
• [54] Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
• [55] Product Information. Serzone (nefazodone). Bristol-Myers Squibb, Princeton, NJ.
• [56] Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
• [57] Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
• [58] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
• [59] Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
• [60] Auclair B, Berning SE, Huitt GA, Peloquin CP "Potential interaction between itraconazole and clarithromycin." Pharmacotherapy 19 (1999): 1439-44. [PMID: 10600094]
• [61] Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
• [62] Anson BD, Weaver JG, Ackerman MJ, et al. "Blockade of HERG channels by HIV protease inhibitors." Lancet 365 (2005): 682-686. [PMID: 15721475]
• [63] Product Information. Prezista (darunavir). Ortho Biotech Inc, Bridgewater, NJ.
• [64] Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.
• [65] Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
• [66] Product Information. Givlaari (givosiran). Alnylam Pharmaceuticals, Cambridge, MA.
• [67] Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
• [68] Product Information. Prolia (denosumab). Amgen USA, Thousand Oaks, CA.
• [69] Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
• [70] Product Information. Vizimpro (dacomitinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
• [71] Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
• [72] Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ.
• [73] Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
• [74] Harper KM, Knapp DJ, Criswell HE, Breese GR "Vasopressin and alcohol: A multifaceted relationship." Psychopharmacology (Berl) 235 (2018): 3363-79. [PMID: 32936259]
• [75] Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
• [76] Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
• [77] Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
• [78] Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
• [79] Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
• [80] Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
• [81] Bennett CL, Nebeker JR, Samore MH, et al "The Research on Adverse Drug Events and Reports (RADAR) project." JAMA 293 (2005): 2131-40. [PMID: 15870417]
• [82] Product Information. Vumerity (diroximel fumarate). Alkermes, Inc, Cambridge, MA.
• [83] Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
• [84] Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
• [85] Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
• [86] Product Information. Synribo (omacetaxine). Teva Pharmaceuticals USA, North Wales, PA.
• [87] Product Information. Varubi (rolapitant). Tesaro Inc., Waltham, MA.
• [88] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
• [89] Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
• [90] Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
• [91] Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
• [92] Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
• [93] Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
• [94] Product Information. Nubeqa (darolutamide). Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ.
• [95] Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
• [96] Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004): 55-6. [PMID: 14722399]
• [97] Product Information. Arcalyst (rilonacept). Regeneron Pharmaceuticals Inc, Tarrytown, NY.
• [98] Product Information. Cimzia (certolizumab). UCB Pharma Inc, Smyrna, GA.
• [99] Product Information. Barhemsys (amisulpride). Acacia Pharma, Inc, Indianapolis, IN.
• [100] CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]
• [101] Product Information. Oxbryta (voxelotor). Global Blood Therapeutics, Inc., South San Francisco, CA.
• [102] Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
• [103] Goto M, Sato M, Kitzazawa H, et.al "Papaverine-induced QT interval prolongation and ventricular fibrillation in a patient with a history of drug-induced QT prolongation." Intern Med 53 (2014): 1629-31. [PMID: 25088875]